L Number	Hits	Search Text	DB	Time stamp
1	945	(514/217,220).CCLS.	USPAT; US-PGPUB	2004/01/28 10:21
2	132	(540/590,588).CCLS.	USPAT; US-PGPUB	2004/01/28 10:21
3	1023	((514/217,220).CCLS.) ((540/590,588).CCLS.)	USPAT; US-PGPUB	2004/01/28 10:21
4	30	(((514/217,220).CCLS.) ((540/590,588).CCLS.)) AND ((ventricul$ ADJ firbillat$) or defribrillat$ OR antiarrhy$)	USPAT; US-PGPUB	2004/01/28 10:23

Day : Wednesday

PALM INTRANET

Date: 1/28/2004
Time: 16:34:10

Inventor Information for 10/069455

Inventor Name	City	State/Country
EREZ, MORDECHAI	TEL AVIV	ISRAEL
LEVY, OFRA	TIKVA	ISRAEL
KEINAN, EHUD	TIMRAT	ISRAEL

Appln Info | Contents | Petition Info | Atty/Agent Info | Continuity Data | Foreign Data

Search Another: Application# Search **or Patent#** Search

PCT / / Search **or PG PUBS #** Search

Attorney Docket # Search

Bar Code # Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1            Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2            "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09    CA/CAplus records now contain indexing from 1907 to the
                    present
 NEWS  4  DEC 08    INPADOC: Legal Status data reloaded
 NEWS  5  SEP 29    DISSABS now available on STN
 NEWS  6  OCT 10    PCTFULL: Two new display fields added
 NEWS  7  OCT 21    BIOSIS file reloaded and enhanced
 NEWS  8  OCT 28    BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS  9  NOV 24    MSDS-CCOHS file reloaded
 NEWS 10  DEC 08    CABA reloaded with left truncation
 NEWS 11  DEC 08    IMS file names changed
 NEWS 12  DEC 09    Experimental property data collected by CAS now available
                    in REGISTRY
 NEWS 13  DEC 09    STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 14  DEC 17    DGENE: Two new display fields added
 NEWS 15  DEC 18    BIOTECHNO no longer updated
 NEWS 16  DEC 19    CROPU no longer updated; subscriber discount no longer
                    available
 NEWS 17  DEC 22    Additional INPI reactions and pre-1907 documents added to CAS
                    databases
 NEWS 18  DEC 22    IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 19  DEC 22    ABI-INFORM now available on STN
 NEWS 20  JAN 27    Source of Registration (SR) information in REGISTRY updated
                    and searchable
 NEWS 21  JAN 27    A new search aid, the Company Name Thesaurus, available in
                    CA/CAplus

 NEWS EXPRESS  DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:31:07 ON 28 JAN 2004

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:31:18 ON 28 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 JAN 2004 HIGHEST RN 642407-31-6
DICTIONARY FILE UPDATES: 27 JAN 2004 HIGHEST RN 642407-31-6

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

```
=> s (C16H15N OR C17H17N)
          1114 C16H15N
          1026 C17H17N
L1        2139 (C16H15N OR C17H17N)

=> s l1 and nrrs = 3
       1760988 NRRS = 3
L2         416 L1 AND NRRS = 3

=> s iminodibenzyl/cn
L3           1 IMINODIBENZYL/CN

=> d l3 str rsd

L3   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Ring System Data

Elemental Analysis EA	Elemental Sequence ES	Size of the Rings SZ	Ring System Formula RF	Ring Identifier RID	RID Occurrence Count
C6-C6-C6N	C6-C6-NC6	6-6-7	C14N	3068.33.8	1

```
=> s 3068.33/rid AND l2
          6137 3068.33/RID
```

L4 17 3068.33/RID AND L2

=> **d scan**

L4 17 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5H-Dibenz[b,f]azepine, 3,7-dimethyl- (7CI)
MF **C16 H15 N**



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)**s 3068.33.8/rid and l2**
'S 3068.33.8/RID AND L2' IS NOT VALID HERE

To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):**0**

=> **s 3068.33.8/rid and l2**
4381 3068.33.8/RID
L5 4 3068.33.8/RID AND L2

=> **d 1-4 ide cbib pi**

L5 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 74074-21-8 REGISTRY
CN 5H-Dibenz[b,f]azepine, 10,11-dihydro-5-(2-propenyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF **C17 H17 N**
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:286423 One-pot synthesis of pharmacologically active diamines via rhodium-catalyzed carbonylative hydroaminomethylation of heterocyclic allylic amines. Rische, Thorsten; Muller, Kai-Sven; Eilbracht, Peter (Organische Chemie I (FB 3), Universitat Dortmund,

Dortmund, D-44221, Germany). Tetrahedron, 55(32), 9801-9816 (English) 1999. CODEN: TETRAB. ISSN: 0040-4020. Publisher: Elsevier Science Ltd..

REFERENCE 2: 98:179189 Phase transfer catalysis in N-alkylations of the pharmaceutical intermediates 5H-dibenz[b,f]azepine and 5H-10,11-dihydrodibenz[b,f]azepine. Gozlan, Igal; Halpern, Marc; Rabinovitz, Mordecai; Avnir, David; Ladkani, David (Dep. Org. Chem., Hebrew Univ. Jerusalem, Jerusalem, 91904, Israel). Journal of Heterocyclic Chemistry, 19(6), 1569-71 (English) 1982. CODEN: JHTCAD. ISSN: 0022-152X.

REFERENCE 3: 93:26248 N-Alkylation of 5-H-dibenz[b,f]azepine and 10,11-dihydro-5H-dibenz[b,f]azepine by phase transfer catalysis. Part 4. Iminodibenzyl derivatives. Hannig, E.; Pech, R.; Dressler, C. (Sekt. Pharm., Martin-Luther-Univ., Halle-Wittenberg, DDR-402, Ger. Dem. Rep.). Pharmazie, 34(10), 670-1 (German) 1979. CODEN: PHARAT. ISSN: 0031-7144.

L5 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 73046-29-4 REGISTRY
CN 5H-Dibenz[b,f]azepine, 5-ethenyl-10,11-dihydro- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF **C16 H15 N**
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 92:111322 Synthesis, characterization, and polymerization of N-vinylarylamines. Lin, John W. P. (Webster Res. Cent., Xerox Corp., Webster, NY, 14580, USA). Journal of Polymer Science, Polymer Chemistry Edition, 17(12), 3797-810 (English) 1979. CODEN: JPLCAT. ISSN: 0449-296X.

L5 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 52902-39-3 REGISTRY
CN 5H-Dibenz[b,f]azepine, 2-ethenyl-10,11-dihydro-5-methyl-, homopolymer (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Poly(N-methyl-2-vinyliminobibenzyl)
MF **(C17 H17 N)x**
CI PMS
PCT Polyvinyl
LC STN Files: CA, CAPLUS

CM 1

CRN 52902-38-2
CMF C17 H17 N



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 81:152676 Synthesis and polymerizability of 5-methyl-2-vinyliminobibenzyl and 10-ethyl-2-vinylphenothiazine. Hyde, P.; Kricka, L. J.; Ledwith, A.; Smith, K. C. (Dep. Inorg. Phys. Indust. Chem., Univ. Liverp., Liverpool, UK). Polymer, 15(6), 387-9 (English) 1974. CODEN: POLMAG. ISSN: 0032-3861.

L5 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 52902-38-2 REGISTRY
CN 5H-Dibenz[b,f]azepine, 2-ethenyl-10,11-dihydro-5-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-Methyl-2-vinyliminobibenzyl
FS 3D CONCORD
MF **C17 H17 N**
CI COM
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 81:152676 Synthesis and polymerizability of 5-methyl-2-vinyliminobibenzyl and 10-ethyl-2-vinylphenothiazine. Hyde, P.; Kricka, L. J.; Ledwith, A.; Smith, K. C. (Dep. Inorg. Phys. Indust. Chem., Univ. Liverp., Liverpool, UK). Polymer, 15(6), 387-9 (English) 1974. CODEN: POLMAG. ISSN: 0032-3861.

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:.

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	43.99	44.20

STN INTERNATIONAL LOGOFF AT 10:38:45 ON 28 JAN 2004

```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1            Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2            "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09    CA/CAplus records now contain indexing from 1907 to the
                    present
 NEWS  4  DEC 08    INPADOC: Legal Status data reloaded
 NEWS  5  SEP 29    DISSABS now available on STN
 NEWS  6  OCT 10    PCTFULL: Two new display fields added
 NEWS  7  OCT 21    BIOSIS file reloaded and enhanced
 NEWS  8  OCT 28    BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS  9  NOV 24    MSDS-CCOHS file reloaded
 NEWS 10  DEC 08    CABA reloaded with left truncation
 NEWS 11  DEC 08    IMS file names changed
 NEWS 12  DEC 09    Experimental property data collected by CAS now available
                    in REGISTRY
 NEWS 13  DEC 09    STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 14  DEC 17    DGENE: Two new display fields added
 NEWS 15  DEC 18    BIOTECHNO no longer updated
 NEWS 16  DEC 19    CROPU no longer updated; subscriber discount no longer
                    available
 NEWS 17  DEC 22    Additional INPI reactions and pre-1907 documents added to CAS
                    databases
 NEWS 18  DEC 22    IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 19  DEC 22    ABI-INFORM now available on STN
 NEWS 20  JAN 27    Source of Registration (SR) information in REGISTRY updated
                    and searchable
 NEWS 21  JAN 27    A new search aid, the Company Name Thesaurus, available in
                    CA/CAplus

 NEWS EXPRESS  DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:26:11 ON 28 JAN 2004

=>
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> file reg
```

```
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                          ENTRY    SESSION
FULL ESTIMATED COST                                        3.78       3.78

FILE 'REGISTRY' ENTERED AT 12:37:07 ON 28 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 JAN 2004  HIGHEST RN 642407-31-6
DICTIONARY FILE UPDATES:  27 JAN 2004  HIGHEST RN 642407-31-6

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> set lcost off
SET COMMAND COMPLETED

=> set cost off
SET COMMAND COMPLETED

=>
L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 12:37:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  30376 TO ITERATE

  3.3% PROCESSED    1000 ITERATIONS                          1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:       597115 TO   617925
PROJECTED ANSWERS:             277 TO      937

L2            1 SEA SSS SAM L1

=> d scan

L2   1 ANSWERS   REGISTRY  COPYRIGHT 2004 ACS on STN
IN   Benzenamine, 4-(2a-aza-1,2(2a)-homo[5,6]fulleren-C60-Ih-2a-yl)-N,N-
     dimethyl- (9CI)
MF   C68 H10 N2
```





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>
L3 STRUCTURE UPLOADED

=> **s 13**
SAMPLE SEARCH INITIATED 12:39:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 997 TO ITERATE

100.0% PROCESSED 997 ITERATIONS 44 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**
PROJECTED ITERATIONS: 18046 TO 21834
PROJECTED ANSWERS: 483 TO 1277

L4 44 SEA SSS SAM L3

=> **d scan**

L4 44 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Molybdenum, tetracarbonylbis(η5-2,4-cyclopentadien-1-yl)[μ-[N-[(2,3-η:2,3-η)-2-propynyl]-5H-dibenz[b,f]azepine-5-carboxamide]]di- (9CI)
MF C32 H24 Mo2 N2 O5
CI CCS

PAGE 1-A



PAGE 2-A



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)**3**

L4 44 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5H-Dibenz[b,f]azepine-5-carboxamide, 10-(acetyloxy)-10,11-dihydro-, (10R)- (9CI)
MF C17 H16 N2 O3

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 44 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 5H-Dibenz[b,f]azepine, 5-[3-(dimethylamino)-1-oxopropyl]-10,11-dihydro-, compd. with 2,4,6-trinitrophenol (1:1) (9CI)
MF C19 H22 N2 O . C6 H3 N3 O7

CM 1



CM 2



L4 44 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Formic acid, compd. with N-[1-(aminoiminomethyl)-3-piperidinyl]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepine-5-carboxamide (1:1) (9CI)
MF C20 H22 N6 O2 . C H2 O2

CM 1



CM 2

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)**0**

=> **s l3 full**
FULL SEARCH INITIATED 12:41:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 20835 TO ITERATE

100.0% PROCESSED 20835 ITERATIONS 1108 ANSWERS
SEARCH TIME: 00.00.01

L5 1108 SEA SSS FUL L3

=>
L6 STRUCTURE UPLOADED

=> **s l6 subset = l5 full**
FULL SUBSET SEARCH INITIATED 12:42:46 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 989 TO ITERATE

100.0% PROCESSED 989 ITERATIONS 26 ANSWERS
SEARCH TIME: 00.00.01

L7 26 SEA SUB=L5 SSS FUL L6

=> **d 1-26 ide cbib pi**

L7 ANSWER 1 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 393513-34-3 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, 10,11-dihydro-α-[[(1-methylethyl)amino]methyl]-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H26 N2 O . Cl H
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry. Rotation (-).



HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:128575 A new class of antiarrhythmic-Defibrillatory agents. Levy, Ofra; Erez, Mordechai; Varon, Dalia; Keinan, Ehud (Technion-Israel Institute of Technology, Department of Chemistry and Institute of Catalysis Science and Technology, Technion City, Haifa, 32000, Israel). Bioorganic & Medicinal Chemistry Letters, 11(22), 2921-2926 (English) 2001. CODEN: BMCLE8. ISSN: 0960-894X. Publisher: Elsevier Science Ltd..

L7 ANSWER 2 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 393513-33-2 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, 10,11-dihydro-α-[[(1-methylethyl)amino]methyl]-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H26 N2 O . Cl H
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry. Rotation (+).



HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:128575 A new class of antiarrhythmic-Defibrillatory agents. Levy, Ofra; Erez, Mordechai; Varon, Dalia; Keinan, Ehud (Technion-Israel Institute of Technology, Department of Chemistry and Institute of Catalysis Science and Technology, Technion City, Haifa, 32000, Israel). Bioorganic & Medicinal Chemistry Letters, 11(22), 2921-2926 (English) 2001. CODEN: BMCLE8. ISSN: 0960-894X. Publisher: Elsevier Science Ltd..

L7 ANSWER 3 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN

RN 393513-32-1 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, 10,11-dihydro-α-[[(1-methylethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)
MF C20 H26 N2 O . Cl H
SR CA
LC STN Files: CA, CAPLUS



HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:128575 A new class of antiarrhythmic-Defibrillatory agents. Levy, Ofra; Erez, Mordechai; Varon, Dalia; Keinan, Ehud (Technion-Israel Institute of Technology, Department of Chemistry and Institute of Catalysis Science and Technology, Technion City, Haifa, 32000, Israel). Bioorganic & Medicinal Chemistry Letters, 11(22), 2921-2926 (English) 2001. CODEN: BMCLE8. ISSN: 0960-894X. Publisher: Elsevier Science Ltd..

L7 ANSWER 4 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 328405-92-1 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-propanol, 10,11-dihydro-α-[[(1-methylethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)
MF C21 H28 N2 O . Cl H
SR CA
LC STN Files: CA, CAPLUS



HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:207730 Preparation of N-aminoacyldibenzazepines and analogs as defibrillating agents. Erez, Mordechai; Levy, Ofra; Keinan, Ehud (Technion Research and Development Foundation Ltd., Israel). PCT Int. Appl. WO 2001015656 A2 20010308, 40 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,

TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM;
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB,
GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English).
CODEN: PIXXD2. APPLICATION: WO 2000-IL510 20000827. PRIORITY: IL
1999-131685 19990901.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001015656	A2	20010308	WO 2000-IL510	20000827
	WO 2001015656	A3	20010830		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

L7 ANSWER 5 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 328405-91-0 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-propanol, 10,11-dihydro-α-[[(1-methylethyl)amino]methyl]-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H28 N2 O . Cl H
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:207730 Preparation of N-aminoacyldibenzazepines and analogs as defibrillating agents. Erez, Mordechai; Levy, Ofra; Keinan, Ehud (Technion Research and Development Foundation Ltd., Israel). PCT Int. Appl. WO 2001015656 A2 20010308, 40 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-IL510 20000827. PRIORITY: IL

1999-131685 19990901.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001015656	A2	20010308	WO 2000-IL510	20000827
	WO 2001015656	A3	20010830		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

L7 ANSWER 6 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 328405-90-9 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-propanol, 10,11-dihydro-α-[[(1-methylethyl)amino]methyl]-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H28 N2 O . Cl H
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:207730 Preparation of N-aminoacyldibenzazepines and analogs as defibrillating agents. Erez, Mordechai; Levy, Ofra; Keinan, Ehud (Technion Research and Development Foundation Ltd., Israel). PCT Int. Appl. WO 2001015656 A2 20010308, 40 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-IL510 20000827. PRIORITY: IL 1999-131685 19990901.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001015656	A2	20010308	WO 2000-IL510	20000827

WO 2001015656 A3 20010830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

L7 ANSWER 7 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 104176-37-6 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, α-[[(2-diethylaminoethyl)ethylamino]methyl]- (6CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H35 N3 O
SR CAOLD
LC STN Files: CA, CAOLD, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 55:8247 5H-Dibenz[b,f]azepine. Schindler, Walter; Hfliger, Franz (Geigy Chemical Corp.). US 2948719 19600809 (Unavailable).
APPLICATION: US .

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2948719		19600809	US	
	CH 364266			CH	
	GB 901691			GB	

L7 ANSWER 8 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 104176-29-6 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, α-[[butyl(2-dimethylaminoethyl)amino]methyl]-3,7-dichloro-10,11-dihydro- (6CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H35 Cl2 N3 O
SR CAOLD
LC STN Files: BEILSTEIN*, CAOLD
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 9 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 103990-31-4 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, 3,7-dichloro-α-[[(2-diethylaminoethyl)amino]methyl]-10,11-dihydro- (6CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H31 Cl2 N3 O
SR CAOLD
LC STN Files: CAOLD



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 10 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 103990-25-6 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, 3,7-dibromo-α-[[(2-diethylaminoethyl)amino]methyl]-10,11-dihydro- (6CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H31 Br2 N3 O
SR CAOLD
LC STN Files: CAOLD



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 11 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 103857-44-9 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, α-[[butyl(2-dimethylaminoethyl)amino]methyl]-10,11-dihydro- (6CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H37 N3 O
SR CAOLD
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 55:8247 5H-Dibenz[b,f]azepine. Schindler, Walter; Hfliger, Franz (Geigy Chemical Corp.). US 2948719 19600809 (Unavailable).
APPLICATION: US .

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2948719		19600809	US	
	CH 364266			CH	
	GB 901691			GB	

L7 ANSWER 12 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 103650-35-7 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, α-[[(2-dimethylaminoethyl)methylamino]methyl]-10,11-dihydro- (6CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H31 N3 O
SR CAOLD
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 55:8247 5H-Dibenz[b,f]azepine. Schindler, Walter; Hfliger, Franz (Geigy Chemical Corp.). US 2948719 19600809 (Unavailable). APPLICATION: US .

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2948719		19600809	US	
	CH 364266			CH	
	GB 901691			GB	

REFERENCE 2: 49:32443 Derivatives of iminodibenzyl. Schindler, W.; Hafliger, F. (Geigy A.-G., Basel, Switz.). Helvetica Chimica Acta, 37, 472-83 (German) 1954. CODEN: HCACAV. ISSN: 0018-019X.

L7 ANSWER 13 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 103644-72-0 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, α-[[(2-dimethylaminoethyl)propylamino]methyl]-10,11-dihydro- (6CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H35 N3 O
SR CAOLD
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 55:8247 5H-Dibenz[b,f]azepine. Schindler, Walter; Hfliger, Franz (Geigy Chemical Corp.). US 2948719 19600809 (Unavailable). APPLICATION: US .

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2948719		19600809	US	
	CH 364266			CH	
	GB 901691			GB	

REFERENCE 2: 49:32443 Derivatives of iminodibenzyl. Schindler, W.; Hafliger, F. (Geigy A.-G., Basel, Switz.). Helvetica Chimica Acta, 37, 472-83 (German) 1954. CODEN: HCACAV. ISSN: 0018-019X.

L7 ANSWER 14 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 103643-90-9 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, α-[[(2-

diethylaminoethyl)amino]methyl]-10,11-dihydro- (6CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H33 N3 O
SR CAOLD
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 55:8247 5H-Dibenz[b,f]azepine. Schindler, Walter; Hfliger, Franz (Geigy Chemical Corp.). US 2948719 19600809 (Unavailable). APPLICATION: US .

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2948719		19600809	US	
	CH 364266			CH	
	GB 901691			GB	

L7 ANSWER 15 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 102374-72-1 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, 3,7-dichloro-α-(diethylaminomethyl)- (6CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H24 Cl2 N2 O
CI COM
SR CAOLD
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, TOXCENTER
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 55:93618 Porphyrin compounds. Kohiga, Misao; Sasaki, Shuei;

Tanaka, Katsutaro; Iijima, Noboru (First Industrial Drug Manufg. Co.). JP 35017489 19601129 Showa (Unavailable). APPLICATION: JP .

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 35017489		19601129	JP	

REFERENCE 2: 55:93617 N-Substituted iminostilbenes. Schindler, Walter (Geigy Chemical Corp.). US 2976281 19610321 (Unavailable). APPLICATION: US .

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2976281		19610321	US	

L7 ANSWER 16 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 101058-97-3 REGISTRY
CN 5-[3-(Diethylamino)-2-hydroxypropyl]-5-methyl-5H-dibenz[b,f]azepinium methyl sulfate (7CI) (CA INDEX NAME)
MF C22 H29 N2 O . C H3 O4 S
SR CAOLD
LC STN Files: CAOLD

CM 1

CRN 101058-96-2
CMF C22 H29 N2 O



CM 2

CRN 21228-90-0
CMF C H3 O4 S



1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 17 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 101058-96-2 REGISTRY
CN 5H-Dibenz[b,f]azepinium, 5-[3-(diethylamino)-2-hydroxypropyl]-5-methyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H29 N2 O
CI COM
SR CAOLD



L7 ANSWER 18 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 100261-05-0 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, 3,7-dichloro-α-[(diethylamino)methyl]-, hydrochloride (7CI) (CA INDEX NAME)
MF C21 H24 Cl2 N2 O . x Cl H
SR CAOLD
LC STN Files: CAOLD
CRN (102374-72-1)



x HCl

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 19 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 97017-93-1 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, α-[(diethylamino)methyl]- (6CI, 7CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H26 N2 O
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, TOXCENTER
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 55:93618 Porphyrin compounds. Kohiga, Misao; Sasaki, Shuei; Tanaka, Katsutaro; Iijima, Noboru (First Industrial Drug Manufg. Co.). JP

35017489 19601129 Showa (Unavailable). APPLICATION: JP .

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 35017489		19601129	JP	

REFERENCE 2: 55:93617 N-Substituted iminostilbenes. Schindler, Walter (Geigy Chemical Corp.). US 2976281 19610321 (Unavailable). APPLICATION: US .

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2976281		19610321	US	

L7 ANSWER 20 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 94760-16-4 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, 3,7-dibromo-α-[(diethylamino)methyl]- (7CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H24 Br2 N2 O
LC STN Files: CAOLD



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 21 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 91325-19-8 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, 10,11-dihydro-α-[(methylamino)methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H22 N2 O
LC STN Files: BEILSTEIN*, CA, CAPLUS, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 101:110767 Tricyclic antidepressant drug immunogens,

antibodies, labeled conjugates, and related derivatives. Buckler, Robert Thomas; Ward, Frederick Edmund (Miles Laboratories, Inc. , USA). Eur. Pat. Appl. EP 107134 A1 19840502, 61 pp. DESIGNATED STATES: R: CH, DE, FR, GB, IT, LI, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1983-110063 19831008. PRIORITY: US 1982-435633 19821021.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 107134	A1	19840502	EP 1983-110063	19831008
	EP 107134	B1	19860409		
	R: CH, DE, FR, GB, IT, LI, NL, SE				
	US 4495281	A	19850122	US 1982-435633	19821021
	IL 69460	A1	19861130	IL 1983-69460	19830809
	CA 1240986	A1	19880823	CA 1983-434320	19830810
	AU 8317879	A1	19840503	AU 1983-17879	19830811
	AU 554345	B2	19860814		
	JP 59132362	A2	19840730	JP 1983-195377	19831020
	JP 02031347	B4	19900712		
	ES 526607	A1	19850201	ES 1983-526607	19831020

L7 ANSWER 22 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 91325-15-4 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, α-[(dimethylamino)methyl]-10,11-dihydro- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H24 N2 O
LC STN Files: BEILSTEIN*, CA, CAPLUS, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 101:110767 Tricyclic antidepressant drug immunogens, antibodies, labeled conjugates, and related derivatives. Buckler, Robert Thomas; Ward, Frederick Edmund (Miles Laboratories, Inc. , USA). Eur. Pat. Appl. EP 107134 A1 19840502, 61 pp. DESIGNATED STATES: R: CH, DE, FR, GB, IT, LI, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1983-110063 19831008. PRIORITY: US 1982-435633 19821021.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 107134	A1	19840502	EP 1983-110063	19831008
	EP 107134	B1	19860409		
	R: CH, DE, FR, GB, IT, LI, NL, SE				
	US 4495281	A	19850122	US 1982-435633	19821021
	IL 69460	A1	19861130	IL 1983-69460	19830809
	CA 1240986	A1	19880823	CA 1983-434320	19830810
	AU 8317879	A1	19840503	AU 1983-17879	19830811
	AU 554345	B2	19860814		
	JP 59132362	A2	19840730	JP 1983-195377	19831020

	JP 02031347	B4	19900712		
	ES 526607	A1	19850201	ES 1983-526607	19831020

REFERENCE 2: 49:56957 Basic derivatives of iminodibenzyl. Hafliger, Franz; Schindler, Walter (J. R. Geigy A.-G.). US 2674596 19540406 (Unavailable). APPLICATION: US .

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2674596		19540406	US	

L7 ANSWER 23 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 61282-28-8 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, 10,11-dihydro-α-[[(2-hydroxyethyl)methylamino]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H26 N2 O2
LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 86:16683 Tricyclic dibenzazepine derivatives. Takashima, Yoshinori; Maruyama, Isamu; Katsube, Junki (Sumitomo Chemical Co., Ltd., Japan). Ger. Offen. DE 2555351 19760610, 60 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1975-2555351 19751209.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2555351	A1	19760610	DE 1975-2555351	19751209
	JP 51068583	A2	19760614	JP 1974-141691	19741209
	JP 58033875	B4	19830722		
	JP 51080881	A2	19760715	JP 1975-2911	19741227
	JP 59039433	B4	19840922		
	JP 51127089	A2	19761105	JP 1975-49891	19750423
	JP 59039435	B4	19840922		
	ZA 7507480	A	19761124	ZA 1975-7480	19751127
	BE 836433	A1	19760609	BE 1975-162573	19751209

L7 ANSWER 24 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 61282-22-2 REGISTRY
CN Acetamide, 2-chloro-N-[3-(5H-dibenz[b,f]azepin-5-yl)-2-hydroxypropyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5H-Dibenz[b,f]azepine, acetamide deriv.
FS 3D CONCORD
MF C26 H25 Cl N2 O2
LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 86:16683 Tricyclic dibenzazepine derivatives. Takashima, Yoshinori; Maruyama, Isamu; Katsube, Junki (Sumitomo Chemical Co., Ltd., Japan). Ger. Offen. DE 2555351 19760610, 60 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1975-2555351 19751209.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2555351	A1	19760610	DE 1975-2555351	19751209
	JP 51068583	A2	19760614	JP 1974-141691	19741209
	JP 58033875	B4	19830722		
	JP 51080881	A2	19760715	JP 1975-2911	19741227
	JP 59039433	B4	19840922		
	JP 51127089	A2	19761105	JP 1975-49891	19750423
	JP 59039435	B4	19840922		
	ZA 7507480	A	19761124	ZA 1975-7480	19751127
	BE 836433	A1	19760609	BE 1975-162573	19751209

L7 ANSWER 25 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 61282-21-1 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, α-[[(phenylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H24 N2 O
LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 86:16683 Tricyclic dibenzazepine derivatives. Takashima, Yoshinori; Maruyama, Isamu; Katsube, Junki (Sumitomo Chemical Co., Ltd., Japan). Ger. Offen. DE 2555351 19760610, 60 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1975-2555351 19751209.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	DE 2555351	A1	19760610	DE 1975-2555351	19751209
	JP 51068583	A2	19760614	JP 1974-141691	19741209
	JP 58033875	B4	19830722		
	JP 51080881	A2	19760715	JP 1975-2911	19741227
	JP 59039433	B4	19840922		
	JP 51127089	A2	19761105	JP 1975-49891	19750423
	JP 59039435	B4	19840922		
	ZA 7507480	A	19761124	ZA 1975-7480	19751127
	BE 836433	A1	19760609	BE 1975-162573	19751209

L7 ANSWER 26 OF 26 REGISTRY COPYRIGHT 2004 ACS on STN
RN 56080-17-2 REGISTRY
CN 5H-Dibenz[b,f]azepine-5-ethanol, 10,11-dihydro-α-[[(2-hydroxy-3-phenoxypropyl)amino]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H30 N2 O3
LC STN Files: BEILSTEIN*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 82:171007 1-Amino-3-phenoxy-2-propanols. Wiedemann, Fritz; Thiel, Max; Stach, Kurt; Dietmann, Karl; Sponer, Gisbert (Boehringer Mannheim G.m.b.H., Fed. Rep. Ger.). Ger. Offen. DE 2339396 19750220, 14 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1973-2339396 19730803.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2339396	A1	19750220	DE 1973-2339396	19730803
	DE 2339396	C2	19840628		
	US 3998810	A	19761221	US 1974-487423	19740710
	US 487423	A1	19760302		
	CA 1037039	A1	19780822	CA 1974-205557	19740724
	GB 1408261	A	19751001	GB 1974-33401	19740729
	NL 7410220	A	19750205	NL 1974-10220	19740730
	NL 176261	B	19841016		
	NL 176261	C	19850318		
	JP 50041829	A2	19750416	JP 1974-87432	19740730
	JP 58043388	B4	19830927		
	AU 7471808	A1	19760205	AU 1974-71808	19740730
	CH 605640	A	19781013	CH 1974-10495	19740730
	FI 7402296	A	19750204	FI 1974-2296	19740731
	FI 59585	B	19810529		
	FI 59585	C	19810910		
	ES 428818	A1	19760816	ES 1974-428818	19740731
	FR 2239994	A1	19750307	FR 1974-26716	19740801
	ZA 7404923	A	19750924	ZA 1974-4923	19740801
	AT 7406313	A	19761215	AT 1974-6313	19740801

AT 338274	B	19770810		
SE 7409989	A	19750204	SE 1974-9989	19740802
SE 421693	B	19820125		
SE 421693	C	19820506		
US 4029783	A	19770614	US 1975-638874	19751208
AT 7606138	A	19761215	AT 1976-6138	19760818
AT 338280	B	19770810		

=> **file caplus**
FILE 'CAPLUS' ENTERED AT 12:44:22 ON 28 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Jan 2004 VOL 140 ISS 5
FILE LAST UPDATED: 27 Jan 2004 (20040127/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> **s l5**
L8 4721 L5

=> **s l7**
L9 10 L7

=> **s l8 and (fibrillat? OR defribrillat? OR antiarrhyth? OR ventricul?)**
9375 FIBRILLAT?
3 DEFRIBRILLAT?
12997 ANTIARRHYTH?
42015 VENTRICUL?
L10 107 L8 AND (FIBRILLAT? OR DEFRIBRILLAT? OR ANTIARRHYTH? OR VENTRICUL?)

=> **s l9 and (fibrillat? OR defribrillat? OR antiarrhyth? OR ventricul?)**
9375 FIBRILLAT?
3 DEFRIBRILLAT?
12997 ANTIARRHYTH?
42015 VENTRICUL?
L11 2 L9 AND (FIBRILLAT? OR DEFRIBRILLAT? OR ANTIARRHYTH? OR VENTRICUL?)

=> **d l11 cbib pi hitstr 1-2**

L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

2001:780018 Document No. 136:128575 A new class of **antiarrhythmic**-Defibrillatory agents. Levy, Ofra; Erez, Mordechai; Varon, Dalia; Keinan, Ehud (Technion-Israel Institute of Technology, Department of Chemistry and Institute of Catalysis Science and Technology, Technion City, Haifa, 32000, Israel). Bioorganic & Medicinal Chemistry Letters, 11(22), 2921-2926 (English) 2001. CODEN: BMCLE8. ISSN: 0960-894X. Publisher: Elsevier Science Ltd..

IT **393513-32-1P 393513-33-2P 393513-34-3P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(dibenzoazepine and oxo-dibenzodiazepine derivs. as new class of **antiarrhythmic-ventricular** defibrillatory agents)

RN 393513-32-1 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-ethanol, 10,11-dihydro-α-[[(1-methylethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 393513-33-2 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-ethanol, 10,11-dihydro-α-[[(1-methylethyl)amino]methyl]-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



HCl

RN 393513-34-3 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-ethanol, 10,11-dihydro-α-[[(1-methylethyl)amino]methyl]-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



HCl

L11 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

2001:167774 Document No. 134:207730 Preparation of N-aminoacyldibenzazepines and analogs as defibrillating agents. Erez, Mordechai; Levy, Ofra; Keinan, Ehud (Technion Research and Development Foundation Ltd., Israel). PCT Int. Appl. WO 2001015656 A2 20010308, 40 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-IL510 20000827. PRIORITY: IL 1999-131685 19990901.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001015656	A2	20010308	WO 2000-IL510	20000827
	WO 2001015656	A3	20010830		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

IT **328405-90-9P** **328405-91-0P** **328405-92-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-aminoacyldibenzazepines and analogs as defibrillating agents)

RN 328405-90-9 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-propanol, 10,11-dihydro-α-[[(1-methylethyl)amino]methyl]-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 328405-91-0 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-propanol, 10,11-dihydro-α-[[(1-methylethyl)amino]methyl]-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 328405-92-1 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-propanol, 10,11-dihydro-α-[[(1-methylethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

=> **d his**

(FILE 'HOME' ENTERED AT 12:26:11 ON 28 JAN 2004)

FILE 'REGISTRY' ENTERED AT 12:37:07 ON 28 JAN 2004
SET LCOST OFF
SET COST OFF
L1 STRUCTURE UPLOADED

```
L2             1 S L1
L3               STRUCTURE UPLOADED
L4            44 S L3
L5          1108 S L3 FULL
L6               STRUCTURE UPLOADED
L7            26 S L6 FULL SUB=L5

     FILE 'CAPLUS' ENTERED AT 12:44:22 ON 28 JAN 2004
L8          4721 S L5
L9            10 S L7
L10          107 S L8 AND (FIBRILLAT? OR DEFRIBRILLAT? OR ANTIARRHYTH? OR VENTRI
L11            2 S L9 AND (FIBRILLAT? OR DEFRIBRILLAT? OR ANTIARRHYTH? OR VENTRI

=> s l10 not l11 and p/dt
       4266592 P/DT
L12           39 L10 NOT L11 AND P/DT

=> sort l12 py
SORT ENTIRE ANSWER SET? (Y)/N:y
PROCESSING COMPLETED FOR L12
L13           39 SORT L12 PY

=> d 1-39 cbib pi abs hitstr

L13  ANSWER 1 OF 39  CAPLUS  COPYRIGHT 2004 ACS on STN
```

1973:405322 Document No. 79:5322 1a, 10b-Dihydro-6H-dibenz[b,f]oxireno[d]azepine-6-carboxamides. Kawashima, Kenya; Ishiguro, Toshihiro (Takeda Chemical Industries, Ltd.). Ger. Offen. DE 2246842 19730405, 15 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1972-2246842 19720923.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2246842	A1	19730405	DE 1972-2246842	19720923
	JP 54039390	B4	19791127	JP 1971-76971	19710930
	JP 48039488	A2	19730609		
	JP 49031685	A2	19740322	JP 1972-74448	19720724
	JP 55017036	B4	19800508		
	JP 49031686	A2	19740322	JP 1972-76324	19720728
	AU 7247034	A1	19740411	AU 1972-47034	19720925
	US 3842091	A	19741015	US 1972-291627	19720925
	AT 323184	B	19750625	AT 1972-323184	19720925
	AT 323179	B	19750625	AT 1972-8219	19720925
	BE 789320	A1	19730327	BE 1972-122442	19720927
	NL 7213177	A	19730403	NL 1972-13177	19720928
	FR 2154714	A1	19730511	FR 1972-34446	19720928
	GB 1402325	A	19750806	GB 1972-44772	19720928
	NO 136495	B	19770606	NO 1972-3480	19720928
	HU 164851	P	19740411	HU 1972-TA1212	19720929
	ES 407133	A1	19751016	ES 1972-407133	19720929
	CA 981667	A1	19760113	CA 1972-152881	19720929
	CH 575950	A	19760531	CH 1972-14280	19720929
	CH 578569	A	19760813	CH 1975-16155	19720929

GI For diagram(s), see printed CA Issue.

AB Seven title compds. [I; R = H, NH2, Me, Pr, (CH2)3NMe2, CH2Ph, or C6H4Me-p], useful as anticonvulsive, antiepileptic, **antiarrhythmic**, and antineuralgic agents, were prepd. by reaction of II with RNH2 and reaction of resulting III with percarboxylic acids (AcOOH or m-ClC6H4CO2OH), or by reaction of II with percarboxylic acids and reaction of the resulting IV

(XY = O) with RNH2 or successively with HCl or HBr and RNH2 via IV (X = Cl, Br, Y = OH).

IT **41359-00-6P 41359-01-7P 41359-02-8P 41359-03-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 41359-00-6 CAPLUS
CN 5H-Dibenz[b,f]azepine-5-carboxamide, N-propyl- (9CI) (CA INDEX NAME)



RN 41359-01-7 CAPLUS
CN 5H-Dibenz[b,f]azepine-5-carboxamide, N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 41359-02-8 CAPLUS
CN 5H-Dibenz[b,f]azepine-5-carboxamide, N-methyl- (9CI) (CA INDEX NAME)



RN 41359-03-9 CAPLUS
CN 5H-Dibenz[b,f]azepine-5-carboxamide, N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 2 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1974:463503 Document No. 81:63503 **Antiarrhythmic** 5-[(3-amino-2-hyroxypropyl)carbamyol]-5H-dibenz[b,f]azepines. Vincent, Michel; Remond, Georges; Laubie, Michel (Science Union et Cie., Societe Francaise de Recherche Medicale). Ger. Offen. DE 2354999 19740522, 21 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1973-2354999 19731102.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2354999	A1	19740522	DE 1973-2354999	19731102
	DE 2354999	B2	19770113		
	DE 2354999	C3	19770915		
	FR 2205319	A1	19740531	FR 1973-38190	19731026
	BE 806854	A1	19740430	BE 1973-137361	19731031
	US 3925369	A	19751209	US 1973-411540	19731031
	NL 7315030	A	19740507	NL 1973-15030	19731101
	NL 161444	C	19800215		
	NL 161444	B	19790917		
	HU 167847	P	19751225	HU 1973-SI1354	19731101
	CH 581626	A	19761115	CH 1973-15379	19731101
	JP 49080081	A2	19740802	JP 1973-123934	19731102
	JP 55016423	B4	19800501		
	ES 420225	A1	19760316	ES 1973-420225	19731103
	GB 1399539	A	19750702	GB 1972-50697	19731105

GI For diagram(s), see printed CA Issue.

AB Nine dibenzazepines [I; X = CH2CH2 or CH:CH; R = H or Cl; R1 = NR2CH2CH(OH)CH2NR3R4 with R2 = H or Me; R3 = H or CH2Ph; R4 = Me, CHMe2, or CMe3; or NR3R4 = morpholino] and one phenothiazine I (X = S) were prepd. by reaction of I (R1 = Cl or OEt) with R2NHCH2CH(OH) CH2NR3R4 and used as **antiarrhythmic** agents in dogs.

IT **53301-49-8P 53301-50-1P 53301-51-2P**
53301-52-3P 53301-55-6P 53301-56-7P
53301-57-8P 53301-58-9P 53478-03-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 53301-49-8 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-N-[2-hydroxy-3-[(1-methylethyl)(phenylmethyl)amino]propyl]-, hydrochloride (9CI) (CA INDEX NAME)



x HCl

RN 53301-50-1 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-N-[2-hydroxy-3-[(1-methylethyl)amino]propyl]-, hydrochloride (9CI) (CA INDEX NAME)



x HCl

RN 53301-51-2 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide, N-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl]-10,11-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



x HCl

RN 53301-52-3 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide, N-[2-hydroxy-3-[(1-methylethyl)(phenylmethyl)amino]propyl]-, hydrochloride (9CI) (CA INDEX NAME)



x HCl

RN 53301-55-6 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-N-[2-hydroxy-3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 53301-56-7 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-N-[2-hydroxy-3-[methyl(phenylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)



RN 53301-57-8 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-N-[2-hydroxy-3-(methylamino)propyl]- (9CI) (CA INDEX NAME)



RN 53301-58-9 CAPLUS
CN 5H-Dibenz[b,f]azepine-5-carboxamide, N-[3-[(1,1-dimethylethyl)(phenylmethyl)amino]-2-hydroxypropyl]-10,11-dihydro-N-methyl- (9CI) (CA INDEX NAME)



RN 53478-03-8 CAPLUS
CN 5H-Dibenz[b,f]azepine-5-carboxamide, 3,7-dichloro-N-[3-[(1,1-dimethylethyl)(phenylmethyl)amino]-2-hydroxypropyl]-10,11-dihydro- (9CI) (CA INDEX NAME)



L13 ANSWER 3 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1976:446442 Document No. 85:46442 N-(2-Hexamethyleniminoalkyl)5H-dibenz[b,f]azepine-5-carboxamides. Yonan, Peter K. (G. D. Searle & Co., USA). Ger. Offen. DE 2533738 19760415, 14 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1975-2533738 19750728.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2533738	A1	19760415	DE 1975-2533738	19750728
	BE 831815	A1	19760128	BE 1975-158683	19750728
	FI 7502157	A	19760130	FI 1975-2157	19750728
	DK 7503420	A	19760130	DK 1975-3420	19750728
	NO 7502655	A	19760130	NO 1975-2655	19750728
	SE 7508532	A	19760130	SE 1975-8532	19750728
	NL 7508972	A	19760202	NL 1975-8972	19750728
	FR 2280385	A1	19760227	FR 1975-23526	19750728
	FR 2280385	B1	19790615		
	JP 51036474	A2	19760327	JP 1975-91841	19750728
	ZA 7504828	A	19760929	ZA 1975-4828	19750728
	AU 7583437	A1	19770203	AU 1975-83437	19750728
	ES 439820	A1	19770416	ES 1975-439820	19750729

GI



I

AB Dibenzazepinecarboxamides I (n = 2, 3), their methiodides, and I (n = 2)·HCl, useful in treating arrhythmia 60-300 mg per i.v. dose, were prepd. by refluxing 5H-dibenz[b,f]azepine-5-carbonyl chloride with the appropriate ω-hexamethyleniminoalkylamines in CHCl3 and NEt3 90 min or by adding Cl(CH2)nNCO to 5H-dibenz[b,f]azepine in CHCl3 at 50-60°, stirring 2 hr, and warming the N-(ω-chloroalkyl)-5H-dibenz[b,f]azepine-5-carboxamide with hexamethylenimine in MeCOEt 20 hr at 65°.

IT **59755-29-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and **antiarrhythmic** activity of)

RN 59755-29-2 CAPLUS

CN 1H-Azepinium, 1-[2-[(5H-dibenz[b,f]azepin-5-ylcarbonyl)amino]ethyl]hexahydro-1-methyl-, iodide (9CI) (CA INDEX NAME)



I^-

IT **59755-27-0P** **59755-28-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and quaternization of)

RN 59755-27-0 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide, N-[2-(hexahydro-1H-azepin-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 59755-28-1 CAPLUS
CN 5H-Dibenz[b,f]azepine-5-carboxamide, N-[3-(hexahydro-1H-azepin-1-yl)propyl]- (9CI) (CA INDEX NAME)



IT **59755-32-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction with hexamethyleneimine)
RN 59755-32-7 CAPLUS
CN 5H-Dibenz[b,f]azepine-5-carboxamide, N-(2-chloroethyl)- (9CI) (CA INDEX NAME)



IT **59755-30-5P 59755-31-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 59755-30-5 CAPLUS
CN 1H-Azepinium, 1-[3-[(5H-dibenz[b,f]azepin-5-ylcarbonyl)amino]propyl]hexahydro-1-methyl-, iodide (9CI) (CA INDEX NAME)



I^-

RN 59755-31-6 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide, N-[2-(hexahydro-1H-azepin-1-yl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

IT **59755-33-8**

RL: RCT (Reactant); RACT (Reactant or reagent)
(reactions of, with hexamethylenimine)

RN 59755-33-8 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide, N-(3-chloropropyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 4 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1981:497617 Document No. 95:97617 10,11-Dihydro-5H-dibenz[b,f]azepines and

their salts. Carstens, Ernst; Wunderlich, Helmut; Stark, Andreas; Kaverina, N. V.; Senova, S. P.; Lyskovtsev, V. V.; Ermakova, S. I.; Grizenko, A. N.; Skoldinov, A. P. (VEB Arzneimittelwerk, Ger. Dem. Rep.). Ger. Offen. DE 3040085 19810604, 33 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1980-3040085 19801024.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3040085	A1	19810604	DE 1980-3040085	19801024
	DE 3040085	C2	19891116		
	DD 152782	Z	19811209	DD 1979-216679	19791105
	DD 152782	B1	19881130		
	AT 8005119	A	19850815	AT 1980-5119	19801015
	AT 380010	B	19860325		
	GB 2065105	A	19810624	GB 1980-35229	19801103
	GB 2065105	B2	19840125		
	CH 646153	A	19841115	CH 1980-8195	19801104
	JP 56090062	A2	19810721	JP 1980-155753	19801105
	JP 60017789	B4	19850507		

GI



I

AB The title compds. (I; R = C1-3 alkyl; R1, R2 = lower alkyl; R1R2N = piperidino, morpholino, etc., n = 1-3) were prepd.; I have **antiarrhythmic** activity without stimulating or depressing the central nervous system (test data tabulated). Thus, 3-amino-10,11-dihydro-5H-dibenz[b,f]azepine reacted with ClCO2Et in EtOH, and the product reacted with Cl(CH2)2COCl in PhMe, then with morpholine to give 76% I (R = Et, R1R2N = morpholino).

IT **78816-48-5P 78816-49-6P 78816-50-9P 78816-55-4P 78816-56-5P 78816-57-6P 78816-58-7P 78816-63-4P 78816-64-5P 78816-67-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 78816-48-5 CAPLUS

CN Carbamic acid, [5-[3-(diethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 78816-49-6 CAPLUS

CN Carbamic acid, [5-[3-(dimethylamino)-1-oxopropyl]-10,11-dihydro-5H-

dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 78816-50-9 CAPLUS
CN Carbamic acid, [5-[3-(dimethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 78816-55-4 CAPLUS
CN Carbamic acid, [5-[3-(diethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78816-56-5 CAPLUS
CN Carbamic acid, [5-[3-(diethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 78816-57-6 CAPLUS

CN Carbamic acid, [5-[3-(dimethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78816-58-7 CAPLUS

CN Carbamic acid, [5-[3-(dimethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 78816-63-4 CAPLUS

CN Carbamic acid, [5-[3-(diethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 78816-64-5 CAPLUS

CN Carbamic acid, [5-[3-(dimethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 78816-67-8 CAPLUS

CN Carbamic acid, [5-[(dimethylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

L13 ANSWER 5 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1983:2496 Document No. 98:2496 Reagents and method for determining ligands in a sample of biological liquids. Wang, Chao Huie Jeffrey; Stroupe, Stephen Denham; Jolley, Michael Ernest (Abbott Laboratories, USA). Ger. Offen. DE 3205506 A1 19820916, 49 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1982-3205506 19820216. PRIORITY: US 1981-235259 19810217; US 1981-329974 19811211.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3205506	A1	19820916	DE 1982-3205506	19820216
	DE 3205506	C2	19961010		
	CA 1178269	A1	19841120	CA 1982-396311	19820216
	US 5066426	A	19911119	US 1984-644172	19840823
	US 4668640	A	19870526	US 1985-730233	19850502

AB Tracers are described for ligand (esp. drugs and hormones) detn. in body fluids by fluorescence polarization immunoassay. The tracers are ligand analogs with a single reactive primary or secondary amino group which are bound to carboxyfluorescein. For example, prepn. of an aminophenobarbital-carboxyfluorescein conjugate is described, as well as assay procedures, for detn. of phenobarbital. Numerous other examples are given.

IT **1676-31-9DP**, reaction products with carboxyfluorescein
83800-52-6DP, reaction products with carboxyfluorescein
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for fluorescence polarization immunoassay)

RN 1676-31-9 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxylic acid, 10,11-dihydro-, hydrazide (7CI, 9CI) (CA INDEX NAME)



RN 83800-52-6 CAPLUS
CN 5H-Dibenz[b,f]azepine, 5-(aminoacetyl)-10,11-dihydro- (9CI) (CA INDEX NAME)



L13 ANSWER 6 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1982:562853 Document No. 97:162853 5-(ω-Aminoacyl)-3-carbalkoxyamino-10,11-dihydro-5H-dibenz[b,f]azepine derivatives and their therapeutic use. Kaverina, N. V.; Lyskovtsev, V. V.; Senova, Z. P.; Gritsenko, A. N.; Ermakova, Z. I.; Skoldinov, A. P.; Carstens, Ernst; Wunderlich, Helmut; Stark, Andreas (Scientific-Research Institute of Pharmacology, Academy of Medical Sciences, U.S.S.R., USSR). Fr. Demande FR 2493314 A1 19820507, 25 pp. (French). CODEN: FRXXBL. APPLICATION: FR 1980-23564 19801105.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2493314	A1	19820507	FR 1980-23564	19801105
	FR 2493314	B1	19830701		

GI



I

AB Title compds. I [n = 1-3; R and R1 are the same or different alkyl, or NRR1 = piperidino, morpholino, a 4-alkyl-1-piperazinyl group, 4-(2-hydroxyethyl)-1-piperazinyl, a 1,4-diazabicyclo[4.m.0]alk-4-yl group (m = 3- 5); R2 = alkyl], which were prepd., showed **antiarrhythmic** activity. A (carbethoxyamino)dibenzazepine deriv. was treated with ClCH2COCl, and the product reacted with Me2NH to give I (n = 1, R = R1 = Me, R2 = Et).

IT **78816-49-6P 78816-55-4P 78816-57-6P 78816-67-8P 83275-55-2P 83275-56-3P 83275-60-9P 83275-61-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and **antiarrhythmic** activity of)

RN 78816-49-6 CAPLUS
CN Carbamic acid, [5-[3-(dimethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 78816-55-4 CAPLUS
CN Carbamic acid, [5-[3-(diethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78816-57-6 CAPLUS
CN Carbamic acid, [5-[3-(dimethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78816-67-8 CAPLUS
CN Carbamic acid, [5-[(dimethylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



\# HCl

RN 83275-55-2 CAPLUS

CN Carbamic acid, [5-[3-(diethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 83275-56-3 CAPLUS

CN Carbamic acid, [5-[(dimethylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 83275-60-9 CAPLUS

CN Carbamic acid, [5-[3-(diethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 83275-61-0 CAPLUS

CN Carbamic acid, [5-[3-(dimethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



IT **78816-48-5P 78816-50-9P 78816-56-5P**
78816-58-7P 78816-63-4P 78816-64-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 78816-48-5 CAPLUS
CN Carbamic acid, [5-[3-(diethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl
RN 78816-50-9 CAPLUS
CN Carbamic acid, [5-[3-(dimethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl
RN 78816-56-5 CAPLUS
CN Carbamic acid, [5-[3-(diethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 78816-58-7 CAPLUS

CN Carbamic acid, [5-[3-(dimethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 78816-63-4 CAPLUS

CN Carbamic acid, [5-[3-(diethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 78816-64-5 CAPLUS

CN Carbamic acid, [5-[3-(dimethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

L13 ANSWER 7 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1983:554812 Document No. 99:154812 Fluorescein derivatives and fluorescence polarization immunoassay methods. Wang, Chao Huei Jeffrey; Stroupe, Stephen Denham; Jolley, Michael Ernest (Abbott Laboratories, USA). Ger. Offen. DE 3245854 A1 19830623, 53 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1982-3245854 19821210. PRIORITY: US 1981-329975 19811211.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3245854	A1	19830623	DE 1982-3245854	19821210
	DE 3245854	C2	19961114		
	CA 1248086	A1	19890103	CA 1982-416022	19821119
	GB 2111491	A1	19830706	GB 1982-33403	19821123
	GB 2111491	B2	19850821		
	AU 8290880	A1	19830616	AU 1982-90880	19821125
	AU 558800	B2	19870212		
	FR 2518096	A1	19830617	FR 1982-20591	19821208
	FR 2518096	B1	19851206		
	BE 895300	A1	19830609	BE 1982-209695	19821209
	JP 58113189	A2	19830705	JP 1982-214749	19821209
	US 4585862	A	19860429	US 1984-577946	19840208
	US 4952691	A	19900828	US 1990-466557	19900117
	US 5391740	A	19950221	US 1993-44927	19930408

AB Aminofluorescein derivs. are described as reagents for ligand detns. in biol. fluids such as serum, plasma, cerebrospinal fluid, amniotic fluid, and urine. The title method combines the specificity of immunoassays with the speed and suitability of the fluorescence polarization method. For example, lidocaine was detd. with a sulfonyllidodocaine - aminofluorescein conjugate and antibody to lidocaine with fluorescence polarization measurement. Polarization decreased with lidocaine concn. from 0 to 10.0 μg/mL. Prepns. of other conjugates are described as well as assays for carbamazepine and phenobarbital.

IT **298-46-4**

RL: ANT (Analyte); ANST (Analytical study)
(detn. of, by fluorescence polarization immunoassay)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



IT **87178-85-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for fluorescence polarization immunoassay)
RN 87178-85-6 CAPLUS
CN 5H-Dibenz[b,f]azepine-5-carboxamide, N-[[[3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5(or 6)-yl]amino]sulfonyl]-(9CI) (CA INDEX NAME)





L13 ANSWER 8 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1989:75346 Document No. 110:75346 Improved process for the preparation of 3-(carbethoxyamino)-5-[(dimethylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepine. Wunderlich, Helmut; Stark, Andreas; Zenker, Lothar; Lohmann, Dieter; Heidrich, Hans Joachim; Jaensch, Hans Joachim (VEB Arzneimittelwerk, Ger. Dem. Rep.). Ger. (East) DD 258224 A1 19880713, 5 pp. (German). CODEN: GEXXA8. APPLICATION: DD 1987-300456 19870305.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 258224	A1	19880713	DD 1987-300456	19870305
	DD 258224	B3	19921217		

GI



I

AB The title compd. [I; R = Me2NCH2CO (II)], an effective **antiarrhythmic** (no data), is prepd. by a safer and more economical process by acylating I

(R = H) with ClCH2COCl in an inert solvent and treating the product, without isolation, with 10-45% aq. Me2NH in the presence of an acid acceptor. A mixt. of 6.0 kg I (R = H) and 30 L PhMe was heated at 75-80° while 2.7 kg ClCH2COCl was added over 1 h, and the mixt. was refluxed 1 h to give I (R = ClCH2CO) in situ. After cooling to 50°, 7.2 L 8.125 N aq. Me2NH was added and the mixt. was heated 4 h at 60-65° to give, after isolation and crystn., 7.4 kg II, a yield of 94.8%.

IT **83275-56-3P**

RL: PREP (Preparation)
(manuf. of, as **antiarrhythmic**, by 1-pot process)

RN 83275-56-3 CAPLUS

CN Carbamic acid, [5-[(dimethylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and aminolysis of, by dimethylamine, in 1-pot process

L13 ANSWER 9 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1990:440739 Document No. 113:40739 Preparation of 11-[[(pyrrolidinylalkyl)amino]alkanoyl]pyrido[2,3-6][1,4]benzodiazepin-6-ones and analogs as **antiarrhythmic** and spasmolytic agents. Mihm, Gerhard; Eberlein, Wolfgang; Engel, Wolfhard; Trummlitz, Guenter; Mayer, Norbert; De Jonge, Adriaan; Doods, Henri (Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.). Ger. Offen. DE 3820346 A1 19891221, 18 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1988-3820346 19880615.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3820346	A1	19891221	DE 1988-3820346	19880615
	SU 1678209	A3	19910915	SU 1989-4614119	19890524
	EP 346745	A1	19891220	EP 1989-110264	19890607
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	NO 8902432	A	19891218	NO 1989-2432	19890613
	NO 168477	B	19911118		
	NO 168477	C	19920226		
	DD 284016	A5	19901031	DD 1989-329535	19890613
	ZA 8904461	A	19910227	ZA 1989-4461	19890613
	IL 90590	A1	19930221	IL 1989-90590	19890613
	DK 8902911	A	19891216	DK 1989-2911	19890614
	FI 8902897	A	19891216	FI 1989-2897	19890614
	JP 02040381	A2	19900209	JP 1989-152047	19890614
	HU 50472	A2	19900228	HU 1989-3089	19890614
	HU 201759	B	19901228		
	AU 8936446	A1	19891221	AU 1989-36446	19890615
	AU 612493	B2	19910711		
	US 5002943	A	19910326	US 1989-366828	19890615

GI



I

II

AB The title compds. [I; A1, A2 = (CH2)1-4; G = 2,3-pyridylenediyl, arylenediyl, Q1-Q4; R1, R2 = H, (hydroxy)alkyl, cycloalkyl; R3 = H, Cl, alkyl; R4 = H, Me; R5, R6 = H, F, Cl, Br, alkyl; R7 = H, Cl, Me; R8 = H, alkyl; R9 = H, halo, alkyl; R10 = H, Me; X = CH, N; X ≠ N when G = 2,3-pyridylenediyl] were prepd. Thus, chloroacetylpyridobenzodiazepinone II (R = COCH2Cl) was stirred 8 h with MeNHCH2CH2Q (Q = N-methyl-2-pyrrolidinyl) in DMF to give II (R = COCH2NMeCH2CH2Q).HCl which had -logED50 = 7.91 mg/kg i.v. against elec. stimulated bradycardia in rats.

IT **127826-80-6P 127826-86-2P 127826-88-4P 127826-89-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of and, as **antiarrhythmic** and spasmolytic agent)

RN 127826-80-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)



2 HCl

RN 127826-86-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[3-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 127826-88-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[methyl[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 127826-89-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[ethyl[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



L13 ANSWER 10 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1990:235347 Document No. 112:235347 Preparation of 11-[[(heterocyclylalkyl)amino]alkanoyl]pyrido[2,3-b][1,4]benzodiazepin-6-ones and analogs as **antiarrhythmic** and spasmolytic agents. Mihm, Gerhard; Eberlein, Wolfgang; Engel, Wolfhard; Trummlitz, Guenter; Mayer, Norbert; Doods, Henri; De Jonge, Adriaan (Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.). Ger. Offen. DE 3820345 A1 19891221, 18 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1988-3820345 19880615.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3820345	A1	19891221	DE 1988-3820345	19880615
	EP 346744	A1	19891220	EP 1989-110262	19890607
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DD 284015	A5	19901031	DD 1989-329534	19890613
	ZA 8904459	A	19910227	ZA 1989-4459	19890613
	IL 90591	A1	19920818	IL 1989-90591	19890613
	DK 8902910	A	19891216	DK 1989-2910	19890614
	FI 8902896	A	19891216	FI 1989-2896	19890614
	NO 8902469	A	19891218	NO 1989-2469	19890614
	NO 168586	B	19911202		
	NO 168586	C	19920311		
	JP 02040371	A2	19900209	JP 1989-152048	19890614
	HU 50471	A2	19900228	HU 1989-3087	19890614
	HU 201758	B	19901228		
	AU 8936448	A1	19891221	AU 1989-36448	19890615
	AU 612495	B2	19910711		

GI



I





II

AB The title compds. [I; A1, A2 = C1-4 alkylene; G = divalent (hetero)aryl groups Q1-Q4; R1 = H, alkyl, cycloalkyl, cycloalkylalkyl; R2 = alkyl, cycloalkyl; R3, R4 = H, F, Cl, Br, alkyl; R5 = H, Cl, Me; R6, R7 = H, alkyl; R7 may addnl. = halo; X = CH, CCl, N; G = Q4 when X ≠ N; Z = O, C1-3 alkylene] were prepd. Thus, chloroacetylpyridobenzodiazepinone II (R = COCH2Cl) was stirred 0.5 h with 1-methyl-2-[2-(methylamino)ethyl]piperidine in DMF contg. Et3N to give 37% II (R = COCH2NMeCH2CH2Q; Q = 1-methyl-2-piperidyl) which had -log IC50 of 7.48 mol/kg i.v. against elec. stimulated bradycardia in rats.

IT **127173-42-6P** **127173-46-0P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as **antiarrhythmic** and spasmolytic agent)

RN 127173-42-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[methyl[3-(1-methyl-2-piperidinyl)propyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 127173-46-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[[2-(hexahydro-1-methyl-1H-azepin-2-yl)ethyl]methylamino]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



L13 ANSWER 11 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Click to References

1991:81629 Document No. 114:81629 Preparation of 5-(aminoalkylcarbonyl)-3-(alkoxycarbonylamino)-5H-dibenz[b,f]azepines as cardiovascular agents. Wunderlich, Helmut; Stark, Andreas; Lohmann, Dieter; Femmer, Klaus; Poppe, Hildegard; Skoldinov, A. P.; Kaverina, N. V.; Grizenko, A. N.; Senova, Z. P.; et al. (VEB Arzneimittelwerk, Ger. Dem. Rep.; Institute of Pharmacology, Academy of Medical Sciences, U.S.S.R.). Ger. (East) DD 280757 A1 19900718, 12 pp. (German). CODEN: GEXXA8. APPLICATION: DD 1985-273083 19850206.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 280757	A1	19900718	DD 1985-273083	19850206

GI



I



II

AB The title compds. (I; R1,R2,R3 = C1-3 alkyl; R2R3N = heterocyclyl; n = 1,2), useful as **antiarrhythmic**/antischemic agents, were prepd. by 1) acylation at N-5 with X(CH2)nCOY (X, Y = halo), followed by amination of the product, or 2) prepn. and dehydrobromination of 10-bromo-5-haloacyl-3-carboalkoxyamino-10,11-dihydro-5H-dibenz[b,f]azepine followed by amination. Thus, 5-chlorocarbonyl-3-ethoxycarbonylamino-10,11-dihydro-5H-dibenz[b,f]azepine was photobrominated with NBS in CCl4 at 76-77° and the product soln. was refluxed with Et3N to give the 10,11-dehydro deriv, which was dechlorocarbonylated with NaOH in Me2CHOH. The product was acylated with ClCH2COCl in refluxing PhMe followed by amination with Me2NH to give title compd. II. I (R1 = Et, R2 = R3 = Et, n = 2) at 1 ng/kg i.v. in rats reduced aconitine-induced arrhythmia by up to 66%.

IT **131712-43-1P 131712-44-2P 131712-45-3P 131712-46-4P 131712-51-1P 131712-52-2P 132070-91-8P 132070-92-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of, as cardiovascular agent)

RN 131712-43-1 CAPLUS

CN Carbamic acid, [5-[(dimethylamino)acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 131712-44-2 CAPLUS

CN Carbamic acid, [5-[(dimethylamino)acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 131712-45-3 CAPLUS

CN Carbamic acid, [5-[3-(diethylamino)-1-oxopropyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 131712-46-4 CAPLUS

CN Carbamic acid, [5-[3-(diethylamino)-1-oxopropyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 131712-51-1 CAPLUS
CN Carbamic acid, [5-[3-(dimethylamino)-1-oxopropyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 131712-52-2 CAPLUS
CN Carbamic acid, [5-[3-(dimethylamino)-1-oxopropyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 132070-91-8 CAPLUS
CN Carbamic acid, [5-[(diethylamino)acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 132070-92-9 CAPLUS
CN Carbamic acid, [5-[(diethylamino)acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

L13 ANSWER 12 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1992:113574 Document No. 116:113574 Oral sustained-release formulations of GS015 (3-carbethoxyamino-5-dimethylaminoacetyl-10,11-dihydro-5H-dibenz[b,f]azepine hydrochloride). Wenzel, Udo; Schubert, Eberhard; Metzner, Juergen; Hennig, Dietmar; Steup, Albrecht (Martin-Luther-Universitaet Halle-Wittenberg, Germany). Ger. (East) DD 295542 A5 19911107, 3 pp. (German). CODEN: GEXXA8. APPLICATION: DD 1987-309499 19871126.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DD 295542	A5	19911107	DD 1987-309499	19871126

AB Sustained release oral GS015 formulations comprise a matrix made of sapond. PVA (av. mol.-wt. 60,000-80,000) contg. 0-3% vinyl acetate (I), and sapond. PVA (low-mol.-wt. 80,000) contg. 10-18% I. Tablets were made of GS015 1,000, PVA (12% I content) 1,680, PVA (3% I content) 620, talc 90 and Mg stearate 30 g. GS015 is a coronary drug and **antiarrhythmic** (no data).

IT **78816-67-8**, GS015
RL: BIOL (Biological study)
(oral sustained-release formulation of, in PVA matrix)

RN 78816-67-8 CAPLUS

CN Carbamic acid, [5-[(dimethylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

L13 ANSWER 13 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1991:247322 Document No. 114:247322 Preparation of 5-(ω-aminoacyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]-diazepin-11-ones as **antiarrhythmics**. Rueger, Carla; Sauer, Wolfgang; Lohmann, Dieter; Poppe, Hildegard; Bartsch, Reni; Likhosherstov, A. M.; Kaverina, N. V.; Skoldinov, A. P.; Grigor'eva, E. K.; et al. (Arzneimittelwerk Dresden G.m.b.H. I. G., Germany). Eur. Pat. Appl. EP 411567 A1 19910206, 25 pp. DESIGNATED STATES: R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE. (German). CODEN: EPXXDW. APPLICATION: EP 1990-114687 19900731. PRIORITY: DD 1989-331279 19890731.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 411567	A1	19910206	EP 1990-114687	19900731
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
DD 293582	A5	19910905	DD 1989-331279	19890731
JP 03291273	A2	19911220	JP 1990-202331	19900730
US 5264432	A	19931123	US 1992-971671	19921104

GI



AB Title compds. [I; R1 = H, Cl; R2, R3 = H, (cyclo)alkyl; R2R3N = morpholino, N-methylpiperazino; n = 3-6], were prepd. Thus, 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one was refluxed 5 h with bromocaproyl chloride to give 65.6% 5-(6-bromocaproyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one. The latter in DMF at 2° was treated with Me2NH in DMF and the mixt. was kept 30 min at 40° to give 61% title compd. I (R1 = H, R2 = R3 = Me, n = 5). I inhibited CaCl2-induced arrhythmia in rats with ED50 = 0.044-0.44 mg/kg.

IT **134000-64-9P 134000-66-1P 134000-67-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as **antiarrhythmic**)

RN 134000-64-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[4-(diethylamino)-1-oxobutyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 134000-66-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[4-(diethylamino)-1-oxobutyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 134000-67-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[5-(diethylamino)-1-oxopentyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



L13 ANSWER 14 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Find References

1991:247164 Document No. 114:247164 Preparation of 3-alkoxycarbonylamino-5-aminoacyl-5H-dibenz[b,f]azepines as **antiarrhythmics**. Wunderlich, Helmut; Stark, Andreas; Lohmann, Dieter; Zenker, Lothar; Bartsch, Reni; Poppe, Hildegard; Skoldinov, A. P.; Kaverina, N. V.; Grizenko, A. N.; et al. (VEB Arzneimittelwerk, Ger. Dem. Rep.). Eur. Pat. Appl. EP 405255 A2 19910102, 20 pp. DESIGNATED STATES: R: AT, CH, DE, ES, FR, GB, IT, LI, SE. (German). CODEN: EPXXDW. APPLICATION: EP 1990-111337 19900615. PRIORITY: DD 1989-330175 19890630.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 405255	A2	19910102	EP 1990-111337	19900615
	EP 405255	A3	19910807		
	R: AT, CH, DE, ES, FR, GB, IT, LI, SE				
	DD 296915	A5	19911219	DD 1989-330175	19890630
	JP 03038570	A2	19910219	JP 1990-169656	19900627
	US 5192760	A	19930309	US 1990-546375	19900629

GI



I

AB The title compds. [I; R = CO(CH2)nCHR2; R1 = alkyl; R2 = H, (cyclo)alkyl, aralkyl, CH2CH2OH; X = CH2CH2, CH:CH; n = 1-5] were prepd. Thus, I (R1 = Et, X = CH2CH2) (II; R = COCH2Cl) was stirred 1 h at 60° and 4 h at 70-75° with aq. EtNH2 in EtOH to give II (R = COCH2NHEt), which had ED73 of 0.09 mg/kg i.v. against aconitine-induced arrhythmias in rats.

IT **132900-42-6P 134068-15-8P 134068-16-9P**
134068-17-0P 134068-18-1P 134068-19-2P
134068-20-5P 134068-21-6P 134068-22-7P
134068-23-8P 134068-24-9P 134068-25-0P
134068-26-1P 134068-27-2P 134068-28-3P
134068-29-4P 134068-30-7P 134068-31-8P
134068-32-9P 134068-33-0P 134068-34-1P
134068-35-2P 134068-36-3P 134068-37-4P
134068-38-5P 134068-39-6P 134068-40-9P
134068-41-0P 134068-42-1P 134068-44-3P
134068-45-4P 134068-46-5P 134068-47-6P
134068-48-7P 134068-49-8P 134068-50-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as **antiarrhythmic** agent)

RN 132900-42-6 CAPLUS

CN Carbamic acid, [5-(aminoacetyl)-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134068-15-8 CAPLUS

CN Carbamic acid, [10,11-dihydro-5-[[(phenylmethyl)amino]acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134068-16-9 CAPLUS

CN Carbamic acid, [10,11-dihydro-5-[[(2-hydroxyethyl)amino]acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134068-17-0 CAPLUS

CN Carbamic acid, [5-[(ethylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134068-18-1 CAPLUS

CN Carbamic acid, [10,11-dihydro-5-[[(1-methylethyl)amino]acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134068-19-2 CAPLUS
CN Carbamic acid, [10,11-dihydro-5-[(propylamino)acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134068-20-5 CAPLUS
CN Carbamic acid, [5-[[(1,1-dimethylethyl)amino]acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134068-21-6 CAPLUS
CN Carbamic acid, [5-[(butylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134068-22-7 CAPLUS
CN Carbamic acid, [5-[(cyclohexylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134068-23-8 CAPLUS
CN Carbamic acid, [5-[(hexylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134068-24-9 CAPLUS
CN Carbamic acid, [10,11-dihydro-5-[(methylamino)acetyl]-5H-dibenz[b,f]azepin-3-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 134068-25-0 CAPLUS
CN Carbamic acid, [10,11-dihydro-5-[[(2-hydroxyethyl)amino]acetyl]-5H-dibenz[b,f]azepin-3-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 134068-26-1 CAPLUS
CN Carbamic acid, [5-[(ethylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 134068-27-2 CAPLUS

CN Carbamic acid, [5-[[(1,1-dimethylethyl)amino]acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 134068-28-3 CAPLUS

CN Carbamic acid, [10,11-dihydro-5-[(methylamino)acetyl]-5H-dibenz[b,f]azepin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 134068-29-4 CAPLUS

CN Carbamic acid, [10,11-dihydro-5-[[(2-hydroxyethyl)amino]acetyl]-5H-dibenz[b,f]azepin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 134068-30-7 CAPLUS

CN Carbamic acid, [5-[(ethylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 134068-31-8 CAPLUS

CN Carbamic acid, [10,11-dihydro-5-[3-[(2-hydroxyethyl)amino]-1-oxopropyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134068-32-9 CAPLUS

CN Carbamic acid, [5-[(methylamino)acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134068-33-0 CAPLUS

CN Carbamic acid, [5-[(ethylamino)acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134068-34-1 CAPLUS

CN Carbamic acid, [5-[3-(ethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134068-35-2 CAPLUS
CN Carbamic acid, [10,11-dihydro-5-[[(1-phenylethyl)amino]acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134068-36-3 CAPLUS
CN Carbamic acid, [10,11-dihydro-5-[[(2-hydroxyethyl)amino]acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl
RN 134068-37-4 CAPLUS
CN Carbamic acid, [10,11-dihydro-5-[[(1-methylethyl)amino]acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl
RN 134068-38-5 CAPLUS
CN Carbamic acid, [5-[[(1,1-dimethylethyl)amino]acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 134068-39-6 CAPLUS

CN Carbamic acid, [5-[(cyclohexylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 134068-40-9 CAPLUS

CN Carbamic acid, [10,11-dihydro-5-[[(2-hydroxyethyl)amino]acetyl]-5H-dibenz[b,f]azepin-3-yl]-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 134068-41-0 CAPLUS

CN Carbamic acid, [5-[(ethylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 134068-42-1 CAPLUS

CN Carbamic acid, [5-[[(1,1-dimethylethyl)amino]acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, 1-methylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 134068-44-3 CAPLUS

CN Carbamic acid, [10,11-dihydro-5-[[(2-hydroxyethyl)amino]acetyl]-5H-dibenz[b,f]azepin-3-yl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 134068-45-4 CAPLUS

CN Carbamic acid, [5-[(ethylamino)acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 134068-46-5 CAPLUS

CN Carbamic acid, [10,11-dihydro-5-[3-[(2-hydroxyethyl)amino]-1-oxopropyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 134068-47-6 CAPLUS

CN Carbamic acid, [5-[(methylamino)acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 134068-48-7 CAPLUS

CN Carbamic acid, [5-[(ethylamino)acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 134068-49-8 CAPLUS

CN Carbamic acid, [5-[3-(ethylamino)-1-oxopropyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 134068-50-1 CAPLUS

CN Carbamic acid, [10,11-dihydro-5-[[(1-phenylethyl)amino]acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

L13 ANSWER 15 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1993:124572 Document No. 118:124572 Preparation of 5-aminoacyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones as **antiarrhythmics** and anticholinergics. Rueger, Carla; Sauer, Wolfgang; Poppe, Hodegard (Arzneimittelwerk Dresden G.m.b.H., Germany). Ger. Offen. DE 4117123 A1 19921126, 9 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1991-4117123 19910525.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4117123	A1	19921126	DE 1991-4117123	19910525

EP 515796 A1 19921202 EP 1992-105394 19920328
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE

GI



I

AB Title compds. [I; R1 = H, Cl; R2 = H, Me; R3, R4 = H, alkyl, (substituted) cycloalkyl, cycloalkylmethyl, phenylalkyl; R3R4N = morpholino, N-methylpiperazino; n = 3-6; with provisos] were prepd. Thus, 5-(6-chlorohexanoyl)-5,10-dihydro-10-methyl-11H-dibenzo[b,e][1,4]diazepin-11-one was refluxed with Et2NH in DMF to give 26% I.HCl (R1 = H, R2 = Me, R3 = R4 = Et, n = 5). The latter inhibited CaCl2-induced arrhythmia in rats with ED50 = 0.033 mg/kg and showed LD50 = 78 mg/kg in rats.

IT **145950-41-0P 145950-43-2P 145950-44-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as **antiarrhythmic** and anticholinergic)

RN 145950-41-0 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[4-(diethylamino)-1-oxobutyl]-5,10-dihydro-10-methyl- (9CI) (CA INDEX NAME)



RN 145950-43-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[4-(diethylamino)-1-oxobutyl]-5,10-dihydro-10-methyl- (9CI) (CA INDEX NAME)



RN 145950-44-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[5-(diethylamino)-1-oxopentyl]-5,10-dihydro-10-methyl- (9CI) (CA INDEX NAME)



L13 ANSWER 16 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1994:158174 Document No. 120:158174 Redox system-labeled antigen, electrochemical detection immunoassay, and assay kit. Degrand, Chantal; Blankespoor, Ronald; Limoges, Benoit; Brossier, Pierre (Centre National de la Recherche Scientifique, Fr.). PCT Int. Appl. WO 9325907 A1 19931223, 54 pp. DESIGNATED STATES: W: JP, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (French). CODEN: PIXXD2. APPLICATION: WO 1993-FR561 19930611. PRIORITY: FR 1992-7089 19920612.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9325907	A1	19931223	WO 1993-FR561	19930611
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	FR 2692357	A1	19931217	FR 1992-7089	19920612

AB Disclosed are a redox system-labeled antigen, a process for the immunoassay of at least one antigen, and a related assay kit. The invention provides a reliable multiassay homogeneous-phase process which is quick, specific, and capable of being automated. The process consists in (1) allowing ≥1 of the antigens to be assayed to compete with the same antigen which is labeled with a redox system (1 of the forms being ionic) against an anti-antigen antibody present in limited quantity; (2) gathering on an electrode, comprising a polyionic film with a polarity opposite to that of the redox system, the labeled antigens not bound to the antibody, so that the labeled antigens become concd. in the film; and (3) measuring the amplified signal supplied by the electrode using an electrochem. detection means connected to the electrode. The redox system for labeling the antigen is e.g. the pyrrolidinyloxy/pyrrolidinyloxonium pair. The method may be used to det. tricyclic antidepressants, antitumor agents, vitamins, alkaloids, pesticides, etc. The method was used to det. nortriptyline, amphetamine, desipramine, and biotin.

IT **298-46-4**, Carbamazepine
RL: ANT (Analyte); ANST (Analytical study)
(detn. of, electrochem. immunoassay for, redox system-labeled antigen in)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 17 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1994:253358 Document No. 120:253358 Cyclodextrin complexes with polymers, drugs, agrochemicals and cosmetics. Loftsson, Thorsteinn (Iceland). Eur. Pat. Appl. EP 579435 A1 19940119, 46 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1993-305280 19930706. PRIORITY: US 1992-912853 19920714.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 579435	A1	19940119	EP 1993-305280	19930706
	EP 579435	B1	19990317		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5324718	A	19940628	US 1992-912853	19920714
	AT 177647	E	19990415	AT 1993-305280	19930706
	ES 2132190	T3	19990816	ES 1993-305280	19930706
	US 5472954	A	19951205	US 1994-240510	19940511

AB A method for enhancing the complexation of a cyclodextrin (I) with a lipophilic and/or water-labile drug, comprising combining ~0.1-70% (wt./vol.) of I and ~0.001-5% (wt./vol.) of a water-sol. polymer in an aq. medium. The polymer and I are dissolved in the aq. medium before the drug is added. To a soln. contg. Na CM-cellulose 0.25 and 2-hydroxypropyl-β-cyclodextrin 10% was added acetazolamide (II) and the soln. was heated at 120° for 20 min and allowed to equilibrate at room temp. for 3 days and amt. of II was detd. The soly. of II was 3.11mg/mL as compared to 0.7 for control contg. only II. Different formulations contg. cyclodextrin complexes with polymers and drugs are disclosed.

IT **298-46-4DP**, Carbamazepine, complexes with cyclodextrin and polymers
RL: PREP (Preparation)
(prepn. of, with enhanced soly.)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 18 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1995:810571 Document No. 123:227691 Preparation of aminocarboxamide **antiarrhythmics**. Sauer, Wolfgang; Schindler, Rudolf; Rueger, Carla; Poppe, Hildegard; Marx, Degenhard; Bartsch, Reni; Kaverina, Natalja; Lichoserstov, Arkadij; Seredenin, Sergej; et al. (Arzneimittelwerk Dresden G.m.b.H., Germany). Ger. Offen. DE 4344648 A1 19950629, 24 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1993-4344648 19931224.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4344648	A1	19950629	DE 1993-4344648	19931224
	CA 2179810	AA	19950706	CA 1993-2179810	19931224
	WO 9518099	A1	19950706	WO 1994-DE1343	19941112

W: CA, CN, CZ, FI, HU, JP, NO, PL, RU, UA, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
EP 736005 A1 19961009 EP 1995-900625 19941112
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE
RU 2134683 C1 19990820 RU 1996-115017 19941112

GI

Q=



AB The title compds. R1(R2)NCO(CH2)nN(R3)(CH2)mN(R4)R5 [I; R1, R2 = H, (un)branched alkyl, cycloalkyl, (un)substituted Ph; R3 = COR7, (un)substituted SO2Ph, pyridylcarbonyl, Q; R4, R5 = (un)branched alkyl, cycloalkyl, (un)substituted Ph; m = 2-4; n = 1-5; NR1R2 and NR4R5 may be a piperidinyl, pyrrolidinyl, morpholinyl, etc.], useful as **antiarrhythmics**, are prepd. Thus, 4-cyano-N-(dicyclohexylcarbamoylmethyl)-N-(2-diethylaminoethyl)benzamide oxalate, m.p. 173-181°, prepd. from 4-cyanobenzoyl chloride, demonstrated **antiarrhythmic** activity.

IT **168089-66-5P 168089-67-6P 168089-82-5P**
168089-83-6P 168089-93-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aminocarboxamide **antiarrhythmics**)

RN 168089-66-5 CAPLUS
CN Benzamide, N-[3-(diethylamino)propyl]-N-[2-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-2-oxoethyl]-4-nitro- (9CI) (CA INDEX NAME)



RN 168089-67-6 CAPLUS
CN Benzamide, N-[3-(diethylamino)propyl]-N-[2-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-2-oxoethyl]-4-nitro-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 168089-66-5
CMF C30 H34 N4 O4



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 168089-82-5 CAPLUS
CN Carbamic acid, [5-[[[2-(diethylamino)ethyl](4-nitrobenzoyl)amino]acetyl]-10,11-dihydro-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 168089-83-6 CAPLUS
CN Benzamide, N-[2-(8-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-N-[3-(diethylamino)propyl]-4-[(methylsulfonyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

HCl

RN 168089-93-8 CAPLUS

CN Benzamide, N-[2-(8-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-N-[3-(diethylamino)propyl]-4-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



IT **168089-40-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of aminocarboxamide **antiarrhythmics** from)
RN 168089-40-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[[[3-(diethylamino)propyl]amino]acetyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

IT **168089-42-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aminocarboxamide **antiarrhythmics** from)
RN 168089-42-7 CAPLUS
CN 5H-Dibenz[b,f]azepine, 5-[[[3-(diethylamino)propyl]amino]acetyl]-10,11-dihydro- (9CI) (CA INDEX NAME)



L13 ANSWER 19 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1997:53617 Document No. 126:70152 5-(omega-Dialkylaminoacetyl)-3-carbethoxyaminoiminostilbenes showing **antiarrhythmic** activity. Skoldinov, A. P.; Kaverina, N. V.; Gritsenko, A. N.; Senova, Z. P.; Lyskovtsev, V. V.; Vunderlikh, G.; Shtark, A.; Loman, D.; Femmer, K.; et al. (Nauchno-Issledovatelskij Institut Farmakologii Amn Sssr, USSR). U.S.S.R. SU 1336505 A1 19960610 From: Izobreteniya 1996, (16), 282-283. (Russian). CODEN: URXXAF. APPLICATION: SU 1985-3913173 19850513.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI SU 1336505	A1	19960610	SU 1985-3913173	19850513

AB Title only translated.

IT **131712-43-1** **132070-91-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
(5-(omega-dialkylaminoacetyl)-3-carbethoxyaminoiminostilbenes showing **antiarrhythmic** activity)

RN 131712-43-1 CAPLUS

CN Carbamic acid, [5-[(dimethylamino)acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 132070-91-8 CAPLUS

CN Carbamic acid, [5-[(diethylamino)acetyl]-5H-dibenz[b,f]azepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 20 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1996:357034 Document No. 125:19027 Oral pharmaceutical and/or nutritional microcapsules comprising polymer coating. Autant, Pierre; Selles, Jean-Philippe; Soula, Gerard (Flamel Technologies, Societe Anonyme, Fr.). Eur. Pat. Appl. EP 709087 A1 19960501, 25 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE. (French). CODEN: EPXXDW. APPLICATION: EP 1995-420286 19951018. PRIORITY: FR 1994-12759 19941018.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 709087	A1	19960501	EP 1995-420286	19951018
	EP 709087	B1	19991229		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	FR 2725623	A1	19960419	FR 1994-12759	19941018
	FR 2725623	B1	19970221		
	CA 2160762	AA	19960419	CA 1995-2160762	19951017
	ZA 9508762	A	19960509	ZA 1995-8762	19951017
	US 6022562	A	20000208	US 1995-544208	19951017
	IL 115646	A1	20000716	IL 1995-115646	19951017
	WO 9611675	A2	19960425	WO 1995-FR1369	19951018
	WO 9611675	A3	19960620		
	W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

AU 9538077	A1	19960506	AU 1995-38077	19951018
BR 9509286	A	19971014	BR 1995-9286	19951018
JP 10509427	T2	19980914	JP 1996-513006	19951018
AT 188117	E	20000115	AT 1995-420286	19951018
ES 2140641	T3	20000301	ES 1995-420286	19951018
IN 184436	A	20000826	IN 1995-DE1913	19951018

AB Microcapsules contg. pharmaceutical or nutritional agents having particle size ≤1000μm and are coated with film-forming polymers are disclosed. Aciclovir 2800.6, PVP 87.1, and water 1301 g were mixed and granulated, then 300 g of microparticles thus obtained were coated with a soln. contg. Et cellulose 120.30, PVP 13.00, castor oil 13.00, magnesium stearate 16.26, acetone 1284.70, and isopropanol 142.70 g.

IT **298-46-4**, Carbamazepine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral pharmaceutical and/or nutritional microcapsules comprising polymer coating)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 21 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

1999:220012 Document No. 130:242336 Pharmaceuticals in parenteral formulations containing plasma protein. Hegedus, Lajos; Krempels, Krisztina; Paal, Krisztina; Petho, Gabor (Human Rt., Hung.). PCT Int. Appl. WO 9913914 A1 19990325, 70 pp. DESIGNATED STATES: W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2.
APPLICATION: WO 1998-HU86 19980917. PRIORITY: HU 1997-9701554 19970918.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9913914	A1	19990325	WO 1998-HU86	19980917
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9893623	A1	19990405	AU 1998-93623	19980917
AU 734695	B2	20010621		
EP 981375	A1	20000301	EP 1998-946629	19980917
EP 981375	B1	20030108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
SI 20189	C	20001031	SI 1998-20067	19980917
JP 2001508806	T2	20010703	JP 1999-517576	19980917

NZ 503302	A	20010831	NZ 1998-503302	19980917
BR 9812469	A	20020205	BR 1998-12469	19980917
AT 230611	E	20030115	AT 1998-946629	19980917
PT 981375	T	20030430	PT 1998-98946629	19980917
ES 2187062	T3	20030516	ES 1998-946629	19980917
CA 2269923	C	20030722	CA 1998-2269923	19980917
RO 118695	B1	20030930	RO 2000-315	19980917
ZA 9808585	A	20000313	ZA 1998-8585	19980918
LV 12493	B	20010120	LV 2000-38	20000314
NO 2000001371	A	20000518	NO 2000-1371	20000316
BG 104245	A	20001130	BG 2000-104245	20000316
LT 4736	B	20001227	LT 2000-18	20000317
US 2004014655	A1	20040122	US 2003-349492	20030121

AB The invention is related to water-sol. products and pharmaceutical formulations in solid or liq. form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aq. soly. and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of noncovalent bonds. It also covers processes for the prepn. of the product and pharmaceutical formulation.

IT **298-46-4**, Carbamazepine
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmaceuticals in parenteral compns. contg. plasma protein)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 22 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

2000:608551 Document No. 133:213151 Pharmaceutical compositions and methods for improved delivery of hydrophobic therapeutic agents. Patel, Manesh V.; Chen, Feng-Jing (Lipocine, Inc., USA). PCT Int. Appl. WO 2000050007 A1 20000831, 98 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US165 20000105. PRIORITY: US 1999-258654 19990226.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000050007	A1	20000831	WO 2000-US165	20000105

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,

SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6294192	B1	20010925	US 1999-258654	19990226
NZ 513810	A	20010928	NZ 2000-513810	20000105
EP 1158959	A1	20011205	EP 2000-901394	20000105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537317	T2	20021105	JP 2000-600619	20000105

AB The present invention relates to triglyceride-free pharmaceutical compns. for delivery of hydrophobic therapeutic agents. Compns. of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon diln. with an aq. solvent, the compn. forms a clear, aq. dispersion of the surfactants contg. the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compns. A pharmaceutical compn. contained cyclosporin 0.14, Cremophor RH-40 0.41, Arlacel186 0.29, sodium taurocholate 0.26, and propylene glycol 0.46 mg.

IT **298-46-4**, 5H-Dibenz[b,f]azepine-5-carboxamide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

RN 298-46-4 CAPLUS
CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 23 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

2000:307141 Document No. 132:331676 Fluorescence immunoassays using analyte (analog)-conjugated porphyrin-silicon complex fluorescent dyes free of aggregation and serum binding. Devlin, Robert Francis; Dandliker, Walter Beach; Arrhenius, Peter Olaf Gustaf (Hyperion, Inc., USA). U.S. US 6060598 A 20000509, 58 pp., Cont.-in-part of U.S. 5,880,287. (English). CODEN: USXXAM. APPLICATION: US 1997-874820 19970613. PRIORITY: US 1990-523601 19900515; US 1990-524212 19900515; US 1991-701449 19910515; US 1991-701465 19910515; US 1994-333603 19941102; US 1994-346098 19941129; US 1995-476544 19950606.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6060598	A	20000509	US 1997-874820	19970613
	US 5403928	A	19950404	US 1991-701449	19910515
	ES 2163393	T3	20020201	ES 1991-912121	19910515
	US 5641878	A	19970624	US 1994-333603	19941102
	US 5677199	A	19971014	US 1994-346098	19941129
	US 5880287	A	19990309	US 1995-476544	19950606

AB Fluorescence immunoassay methods are provided which use fluorescent dyes which are free of aggregation and serum binding. Such immunoassay methods

are thus, particularly useful for the assay of biol. fluids, such as serum, plasma, whole blood and urine. The compds. of the invention, whose prepn. is described, include silicon complexes with porphyrin derivs. which are linked to an analyte or analog thereof , e.g. a caged dicarboxy silicon phthalocyanine digoxin probe.

IT **298-46-4**, Carbamazepine
RL: ANT (Analyte); ANST (Analytical study)
(fluorescence immunoassays using analyte (analog)-conjugated porphyrin-silicon complex fluorescent dyes free of aggregation and serum binding)

RN 298-46-4 CAPLUS
CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



IT **298-46-4D**, Carbamazepine, conjugates with porphyrin-silicon complexes
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(fluorescence immunoassays using analyte (analog)-conjugated porphyrin-silicon complex fluorescent dyes free of aggregation and serum binding)

RN 298-46-4 CAPLUS
CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 24 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

2001:796365 Document No. 135:327328 High-throughput screening method for identifying drug candidates producing reactive metabolites. Avery, Michael J.; Chen, Weichao G.; Fouda, Hassan G. (Pfizer Products Inc., USA). Eur. Pat. Appl. EP 1150120 A2 20011031, 12 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO. (English). CODEN: EPXXDW. APPLICATION: EP 2001-303546 20010419. PRIORITY: US 2000-PV199698 20000426.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1150120	A2	20011031	EP 2001-303546	20010419
	EP 1150120	A3	20011107		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 2002034729	A1	20020321	US 2001-837674	20010418

JP 2002238597 A2 20020827 JP 2001-125758 20010424

AB The invention provides a high-throughput method for identifying drug candidates which produce reactive metabolites that contribute to toxicity of the drug products, comprising: incubating said drug candidate with a liver microsomal drug metabolizing enzyme system in the presence of glutathione and detecting glutathione conjugates by tandem mass spectrometry.

IT **298-46-4**, Carbamazepine
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(high-throughput screening method for identifying drug candidates producing reactive metabolites)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



IT **298-46-4D**, 5H-Dibenz[b,f]azepine-5-carboxamide, conjugates with glutathione
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(high-throughput screening method for identifying drug candidates producing reactive metabolites)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 25 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Chng References

2001:762800 Document No. 135:322726 A pharmaceutical composition containing a nicotine receptor agonist and an analgesic for treatment of acute, chronic pain and/or neuropathic pain and migraines. Coe, Jotham Wadsworth; Harrigan, Edmund Patrick; O'Neill, Brian Thomas; Sands, Steven Bradley; Watsky, Eric Jacob (Pfizer Products Inc., USA). PCT Int. Appl. WO 2001076576 A2 20011018, 41 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English).

CODEN: PIXXD2. APPLICATION: WO 2001-IB391 20010316. PRIORITY: US 2000-PV195738 20000407.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001076576	A2	20011018	WO 2001-IB391	20010316
	WO 2001076576	A3	20020620		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2001036943	A1	20011101	US 2000-740307	20001218
	EP 1272218	A2	20030108	EP 2001-910097	20010316
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001009837	A	20030121	BR 2001-9837	20010316
	JP 2003530345	T2	20031014	JP 2001-574094	20010316
	BG 107138	A	20030530	BG 2002-107138	20020923
	US 2003133951	A1	20030717	US 2003-348381	20030121

AB Oral, parenteral or transdermal compns. are disclosed for the treatment of acute, chronic and/or neuropathic pain. The pharmaceutical compns. are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an analgesic agent and a pharmaceutically acceptable carrier. The analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anticonvulsants, antihypertensives, **antiarrhythmics**, antihistamines, steroids, caffeine, N-type calcium channel antagonists and botulinum toxin. The method of using these compds. and a method of treating acute, chronic and/or neuropathic pain and migraine in a mammal including a human is also disclosed.

IT **298-46-4**, Carbamazepine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. contg. nicotine receptor agonist and analgesic for treatment of acute, chronic pain and/or neuropathic pain and migraines)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 26 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

2003:1215 Document No. 138:61315 Controlled and sustained release dosage

forms containing hydrophilic carriers and diffusion enhancers. Chhabra, Harinderpal; Sarkar, Shyamal K. (USA). U.S. US 6500459 B1 20021231, 23 pp. (English). CODEN: USXXAM. APPLICATION: US 1999-358732 19990721.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6500459	B1	20021231	US 1999-358732	19990721

AB A pharmaceutical compn. for controlled onset and sustained release of an active ingredient, comprises: (i) a core comprising: (a) an active ingredient; (b) a hydrophilic carrier; (c) a hydrodynamic diffusion enhancer; and optionally (d) conventional excipients selected from the group consisting of binders, fillers and lubricants and combinations thereof; and (ii) a functional coating membrane surrounding the core. Thus, 240 g verapamil-HCl was sieved through a mesh sieve and blended with 150 g E50 premium HPMC. To this blend was added 270.0 g croscarmellose sodium and mixed for 15 min. This blend was granulated with PVP K-29/32 soln. in iso-PrOH (30% wt./wt.). The wet mass obtained in the above step was dried at 60° for 3 h. After drying, the granules were passed a mesh sieve. The granules were then mixed with 2.5 g of Magnesium Stearate and 15 g of Stearic acid in a V blender. This granule blend was compressed in a tablet press by using appropriate size tooling. The granules were then mixed with 2.5 g of Mg stearate and 15 g of stearic acid in a V blender. This granule blend was compressed in a tablet press by using appropriate size tooling. These tablets were then coated by using a perforated coating pan. A seal coating membrane was applied on the surface of tablets to achieve a wt. gain of 1.66% of the wt. of the core. The seal coating dispersion of Opadry Clear in water at 10% was sprayed on to the surface of the tablets by using a perforated coating pan.

IT **298-46-4**, Carbamazepine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled and sustained release dosage forms contg. hydrophilic carriers and diffusion enhancers)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 27 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

2002:964194 Document No. 138:33355 Treating nerve pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels (HCN). Chaplan, Sandra; Dubin, Adrienne; Lee, Doo Hyun; Liu, Changlu (Ortho-McNeil Pharmaceutical, Inc., USA; The Regents of the University of California). PCT Int. Appl. WO 2002100408 A2 20021219, 133 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US16910 20020530. PRIORITY: US 2001-PV297108

20010608; US 2001-PV347945 20011107; US 2002-PV373012 20020416.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002100408	A2	20021219	WO 2002-US16910	20020530
	WO 2002100408	A3	20030731		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2003022812	A1	20030130	US 2002-158684	20020530
	US 2003022813	A1	20030130	US 2002-158711	20020530

AB Markedly enhanced activity of pacemaker (hyperpolarization-activated, cation-nonselective, HCN) ion channels governs spontaneous firing in sensory cells of allodynic rats. An HCN ion channel specific blocker, ZD7288, dose-dependently and completely suppresses allodynia. Nerve injury increases the population of large DRG neurons expressing a high d. of Ih and modulates HCN mRNA expression. New methods of treating pain by targeting HCN pacemaker channels are developed. In addn., new methods for identifying compns. useful for treating pain are disclosed.

IT **298-46-4**, Carbamazepine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating nerve pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels (HCN))

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 28 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

2002:964124 Document No. 138:33351 Treating nerve pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels (HCN). Chaplan, Sandra; Dubin, Adrienne; Guo, Hong-Qing; Lee, Doo Hyun; Liu, Changlu; Luo, Lin; Brown, Sean (Ortho-McNeil Pharmaceutical, Inc., USA). PCT Int. Appl. WO 2002100328 A2 20021219, 134 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US17553 20020530. PRIORITY: US 2001-PV297108 20010608; US 2001-PV347945 20011107; US 2002-PV373012 20020416.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2002100328	A2	20021219	WO 2002-US17553	20020530
	WO 2002100328	A3	20030530		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2003022812	A1	20030130	US 2002-158684	20020530
	US 2003022813	A1	20030130	US 2002-158711	20020530

AB Markedly enhanced activity of pacemaker (hyperpolarization-activated, cation-nonselective, HCN) ion channels governs spontaneous firing in sensory cells of allodynic rats. An HCN ion channel specific blocker, ZD7288, dose-dependently and completely suppresses allodynia. Nerve injury increases the population of large DRG neurons expressing a high d. of Ih and modulates HCN mRNA expression. New methods of treating pain by targeting HCN pacemaker channels are developed. In addn., new methods for identifying compns. useful for treating pain are disclosed.

IT **298-46-4**, Carbamazepine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating nerve pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels (HCN))

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 29 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

2002:428760 Document No. 137:24314 Methods and apparatus for determining and utilizing the viscosity of circulating blood over a range of shear rates for diagnostics and treatment. Kensey, Kenneth; Hokanson, Charles (Visco Technologies, Inc., USA; Rheologics, Inc.). PCT Int. Appl. WO 2002043806 A2 20020606, 98 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US44352 20011127. PRIORITY: US 1997-966076 19971107; US 2000-727950 20001201; US 2001-819924 20010328; US 2001-828761 20010409; US 2001-839785 20010420.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002043806	A2	20020606	WO 2001-US44352	20011127

WO 2002043806 A3 20030327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2301161	AA	19990304	CA 1998-2301161	19980826
NZ 502905	A	20010831	NZ 1998-502905	19980826
JP 2001514384	T2	20010911	JP 2000-507994	19980826
NO 2000000944	A	20000225	NO 2000-944	20000225
US 2002061835	A1	20020523	US 2001-828761	20010409
US 2003078517	A1	20030424	US 2001-839785	20010420
AU 2002026986	A5	20020611	AU 2002-26986	20011127

AB Various methods are provided for detg. and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

IT **28721-07-5**, Oxcarbazepine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and app. for detg. and utilizing the viscosity of circulating blood over a range of shear rates for diagnostics and treatment)

RN 28721-07-5 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo- (8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 30 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

2002:392219 Document No. 136:406945 Methods for in vivo drug delivery based on monitoring blood flow parameters. Kensey, Kenneth R. (USA). U.S. Pat. Appl. Publ. US 2002061835 A1 20020523, 40 pp., Cont.-in-part of U.S. Ser. No. 727,950. (English). CODEN: USXXCO. APPLICATION: US 2001-828761 20010409. PRIORITY: US 1997-919906 19970828; US 1999-439795 19991112; US 2000-501856 20000210; US 2000-628401 20000801; US 2000-727950 20001201.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 2002061835 A1 20020523 US 2001-828761 20010409
US 6019735 A 20000201 US 1997-919906 19970828
CA 2301161 AA 19990304 CA 1998-2301161 19980826
NZ 502905 A 20010831 NZ 1998-502905 19980826
JP 2001514384 T2 20010911 JP 2000-507994 19980826
US 6322524 B1 20011127 US 1999-439795 19991112
US 6322525 B1 20011127 US 2000-501856 20000210
NO 2000000944 A 20000225 NO 2000-944 20000225
US 6428488 B1 20020806 US 2000-615340 20000712
US 2001039828 A1 20011115 US 2001-789350 20010221
US 2002007664 A1 20020124 US 2001-897164 20010702
US 6484565 B2 20021126
WO 2002043806 A2 20020606 WO 2001-US44352 20011127
WO 2002043806 A3 20030327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002026986 A5 20020611 AU 2002-26986 20011127
US 2002088953 A1 20020711 US 2001-33841 20011227
US 6624435 B2 20030923
WO 2002079778 A2 20021010 WO 2002-US3984 20020207
WO 2002079778 A3 20030710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2002184941 A1 20021212 US 2002-156165 20020528
US 6571608 B2 20030603

AB Various methods are provided for detg. and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

IT **28721-07-5**, Oxcarbazepine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for in vivo drug delivery based on monitoring blood flow parameters)

RN 28721-07-5 CAPLUS
CN 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo- (8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 31 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

2002:185688 Document No. 136:252567 Methods for drug administration and distribution based on monitoring blood viscosity and other parameters for diagnostics and treatment. Kensey, Kenneth (USA). U.S. Pat. Appl. Publ. US 2002032149 A1 20020314, 46 pp., Cont.-in-part of U.S. Ser. No. 819,924. (English). CODEN: USXXCO. APPLICATION: US 2001-841389 20010424. PRIORITY: US 1997-919906 19970828; US 1999-439795 19991112; US 2000-501856 20000210; US 2000-628401 20000801; US 2000-727950 20001201; US 2001-819924 20010328.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002032149	A1	20020314	US 2001-841389	20010424
	US 6019735	A	20000201	US 1997-919906	19970828
	CA 2301161	AA	19990304	CA 1998-2301161	19980826
	NZ 502905	A	20010831	NZ 1998-502905	19980826
	JP 2001514384	T2	20010911	JP 2000-507994	19980826
	US 6322524	B1	20011127	US 1999-439795	19991112
	US 6322525	B1	20011127	US 2000-501856	20000210
	NO 2000000944	A	20000225	NO 2000-944	20000225
	US 6428488	B1	20020806	US 2000-615340	20000712
	US 2001039828	A1	20011115	US 2001-789350	20010221
	US 2002007664	A1	20020124	US 2001-897164	20010702
	US 6484565	B2	20021126		
	US 2002088953	A1	20020711	US 2001-33841	20011227
	US 6624435	B2	20030923		
	WO 2002079778	A2	20021010	WO 2002-US3984	20020207
	WO 2002079778	A3	20030710		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2002184941	A1	20021212	US 2002-156165	20020528
	US 6571608	B2	20030603		

AB Various methods are provided for detg. and utilizing the viscosity of the circulating blood of a living being, i.e., a human, over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell

deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the afore mentioned blood parameters are used to adjust distribution of a substance through the bloodstream. For example, when blood viscosity is a blood flow parameter monitored, an agent is selected from i.v. diluents, red blood cell deformability agents, antiurea agents, oral contraceptives, antidiabetic agents, **antiarrhythmics**, antihypertensives, antihyperlipidemics, antiplatelet agents, appetite suppressants, antiobesity agents, blood modifiers, smoking deterrent agents, and nutritional supplements.

IT **28721-07-5**, Oxcarbazepine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(app. and methods for monitoring blood viscosity and other parameters in drug delivery for diagnostics and treatment)

RN 28721-07-5 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo- (8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 32 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Click for References

2002:10274 Document No. 136:64149 6H-Isoindolo[2,1-a]indoles or 5,6-dihydroindolo[2,1-a]isoquinolinesas subtype-selective melatonergics for therapeutic use. Jones, Robert M. (Cognetix, Inc., USA). PCT Int. Appl. WO 2002000215 A1 20020103, 40 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US19958 20010622. PRIORITY: US 2000-PV304189 20000623; US 2001-PV264695 20010130.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002000215	A1	20020103	WO 2001-US19958	20010622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001068677	A5	20020108	AU 2001-68677	20010622

US 2002040018 A1 20020404 US 2001-886609 20010622

AB The invention discloses the use of MT2 selective melatonergics as anticonvulsant agents and as analgesic agents. More specifically, the invention discloses the use of 6H-isoindolo[2,1-a]indoles or 5,6-dihydroindolo[2,1-a]isoquinolines which have melatonin agonist activity and which are selective for the MT2 receptor as anticonvulsant agents or analgesic agents. The invention further relates to the use of 5,6-dihydroindolo[2,1-a]isoquinolines and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles which have melatonin antagonist activity and which are selective for the MT2 receptor as pharmacol. tools for delineation of physiol. responses governed by MT2 receptor activation either by melatonin or selective agonists disclosed herein and for treatment of disorders assocd. with overprodn. of melatonin such as seasonal affective disorder (SAD) and shift work syndrome. Such melatonin antagonists are also useful for treating Parkinson's Disease.

IT **298-46-4**, Tegretol
RL: PAC (Pharmacological activity); BIOL (Biological study)
(isoindoloindole derivs. and dihydroindoloisoquinoline derivs. as subtype-selective melatonergics for therapeutic use)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 33 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

2003:971868 Document No. 140:19871 Delayed release drug delivery systems containing polymers and method for preparation by mixing and compacting. Hanshermann, Franke; Lennartz, Peter; Raimer, Joern (Desitin Arzneimittel Gmbh, Germany). PCT Int. Appl. WO 2003101428 A1 20031211, 32 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (German). CODEN: PIXXD2. APPLICATION: WO 2003-EP5115 20030515. PRIORITY: DE 2002-10224170 20020531.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003101428	A1	20031211	WO 2003-EP5115	20030515

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10224170 A1 20031211 DE 2002-10224170 20020531

AB The invention relates to a pharmaceutical compn., which has a delayed active substance release and can be obtained by means of a special compacting method for which org. solvents and water are not required. Said pharmaceutical compn. preferably exists in the form of individual active substance compartments or breaks down into compartments of this type when brought into contact with aq. media. Various types of drugs can be formulated with acrylic copolymers. Thus 30 kg of oxcarbazepine and 9 kg of Eudragit RSPO were mixed in a quick mixer (Diosna P 100); the mixt. was compacted using a a Gerteis 3 W-Polygran roller compactor applying 15-40 kN/cm at 80°C. The product was disintegrated by forced sieving and classified through a mash. The particles were encapsulated in hard gel capsules.

IT **28721-07-5**, Oxcarbazepine
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(delayed release drug delivery systems contg. polymers and method for prepn. by mixing and compacting)

RN 28721-07-5 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo- (8CI, 9CI) (CA INDEX NAME)



IT **298-46-4**, Carbamazepin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(delayed release drug delivery systems contg. polymers and method for prepn. by mixing and compacting)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 34 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

2003:818270 Document No. 139:312459 Oral aqueous pharmaceutical suspensions for modified release of drugs. Castan, Catherine; Guimberteau, Florence; Meyrueix, Remi (Flamel Technologies, Fr.). PCT Int. Appl. WO 2003084518 A2 20031016, 33 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ,

BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (French). CODEN: PIXXD2. APPLICATION: WO 2003-FR1096 20030407. PRIORITY: FR 2002-4409 20020409; FR 2002-10847 20020902.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003084518	A2	20031016	WO 2003-FR1096	20030407

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AB The invention concerns liq. pharmaceutical formulations, for oral delivery, with modified release of drugs excluding amoxicillin and consisting of suspensions of coated particles of active principles (microcapsules). The microcapsules constituting the dispersed phase of the suspension are designed to enable modified release of the drugs, in accordance with a profile which remains unaltered during the shelf life of the liq. suspension. Therefore, a coating compn. is selected which is specific to the microcapsules consisting of at least 4 components enabling preservation of the microcapsules in water without altering their properties of modified release of the active principle, the liq. phase being furthermore satd. with drugs. Thus, microcapsules were prepd. from 1000 g acyclovir and 30 g PVP to form the granules, the resulting granules were coated with Et cellulose and castor oil. He microcapsules were put in a phosphate buffer suspension.

IT **298-46-4**, Carbamazepine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral aq. pharmaceutical suspensions for modified release of drugs)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 35 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

2003:696722 Document No. 139:219350 Pharmaceutical dosage forms coated with and acrylic copolymers. Petereit, Hans-Ulrich; Suefke, Thomas; Meier, Christian; Schnabel, Michael; Blesing, Ingrid; Grimm, Stefan (Roehm G.m.b.H. & Co. K.-G., Germany). PCT Int. Appl. WO 2003072087 A1 20030904,

49 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (German). CODEN: PIXXD2.
APPLICATION: WO 2003-EP934 20030130. PRIORITY: DE 2002-10208335 20020227.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003072087	A1	20030904	WO 2003-EP934	20030130

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	DE 10208335	A1	20030904	DE 2002-10208335	20020227

AB The invention relates to a method for producing a pharmaceutical dosage form as tablets, pellets and/or in the form of an active ingredient-contg. matrix, whereby the tablets, pellets and/or active ingredient-contg. matrix contain a pharmaceutical active ingredient and a copolymer serving as a coating agent and/or binding agent, and optionally contain a core and pharmaceutically common additives. According to the invention, the copolymer, the pharmaceutical active ingredient, the optionally present core and/or the pharmaceutically common additives are processed using known techniques by melting, injection molding, extrusion, wet granulation, casting, dipping, spreading out, spraying on, or pressing to form tablets, pellets and/or an active ingredient-contg. matrix. The inventive method is characterized in that a copolymer is used that consists of 20 to 34 wt. % methacrylic acid, 20 to 69 wt. % methylacrylate and 0 to 40 wt. % ethylacrylate and, optionally, of 0 to 10 wt. % of addnl. vinylically copolymerizable monomers with the provision that the glass transition temp. of the copolymer is no higher than 60° according to ISO 11357-2, Item 3.3.3. The invention also relates to the pharmaceutical dosage form produced according to this method, said copolymer and the use thereof. Thus a copolymer was prepd. using the monomers: Me acrylate 40; Et acrylate 30; methacrylic acid 30. An emulsion polymerizate contg. 30% of the copolymer was mixed with 0.85% sodium lauryl sulfate (in relation to the copolymer); the fluid was dried to a film; the film was sol. in an artificial intestinal juice at pH 6.8.

IT **298-46-4**, Carbamazepin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical dosage forms coated with and acrylic copolymers)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 36 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

2003:633448 Document No. 139:185666 Coated pharmaceutical tablets with speckled appearance. Martino, Alice C.; Noack, Robert M.; Pierman, Steven A. (Pharmacia Corporation, USA). PCT Int. Appl. WO 2003066030 A2 20030814, 30 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US3837 20030206. PRIORITY: US 2002-PV355705 20020207.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003066030	A2	20030814	WO 2003-US3837	20030206
	WO 2003066030	A3	20031016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2003180357	A1	20030925	US 2003-359939	20030206

AB A pharmaceutical tablet is provide comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-sol. dye distributed in a matrix and (b) the coating comprises gellan gum. The tablet is suitable for peroral or intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject. The tablet has a speckled appearance that renders the tablet readily identifiable.

IT **298-46-4**, Carbamazepine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (active ingredients for coated pharmaceutical tablets with speckled appearance)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 37 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

2003:633447 Document No. 139:185665 Pharmaceutical dosage form for mucosal delivery. Martino, Alice C.; Pierman, Steven A.; Noack, Robert M.; Britten, Nancy (Pharmacia Corporation, USA). PCT Int. Appl. WO 2003066029 A2 20030814, 34 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US3836 20030206. PRIORITY: US 2002-PV355703 20020207.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003066029	A2	20030814	WO 2003-US3836	20030206
	WO 2003066029	A3	20031016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2003235617	A1	20031225	US 2003-360167	20030206

AB A pharmaceutical tablet is provided comprising an intraorally disintegratable core and an excipient coating adherent thereto, wherein the coating comprises gellan gum. The tablet is suitable for intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject, at least in part by absorption of the drug via oral mucosa of the subject.

IT **298-46-4**, Carbamazepine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(active ingredients for coated sublingual tablets)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 38 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

2003:319495 Document No. 138:343864 In vivo delivery methods and compositions. Kensey, Kenneth (USA). U.S. Pat. Appl. Publ. US 2003078517 A1 20030424, 45 pp., Cont.-in-part of U.S. Ser. No. 819,924. (English). CODEN: USXXCO. APPLICATION: US 2001-839785 20010420. PRIORITY: US 1997-919906 19970828; US 1999-439795 19991112; US 2000-501856 20000210; US 2000-628401 20000801; US 2000-727950 20001201; US 2001-819924 20010328.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003078517	A1	20030424	US 2001-839785	20010420
	US 6019735	A	20000201	US 1997-919906	19970828
	CA 2301161	AA	19990304	CA 1998-2301161	19980826
	NZ 502905	A	20010831	NZ 1998-502905	19980826
	JP 2001514384	T2	20010911	JP 2000-507994	19980826
	US 6322524	B1	20011127	US 1999-439795	19991112
	US 6322525	B1	20011127	US 2000-501856	20000210
	NO 2000000944	A	20000225	NO 2000-944	20000225
	US 6428488	B1	20020806	US 2000-615340	20000712
	US 2001039828	A1	20011115	US 2001-789350	20010221
	US 2002007664	A1	20020124	US 2001-897164	20010702
	US 6484565	B2	20021126		
	WO 2002043806	A2	20020606	WO 2001-US44352	20011127
	WO 2002043806	A3	20030327		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002026986	A5	20020611	AU 2002-26986	20011127
	US 2002088953	A1	20020711	US 2001-33841	20011227
	US 6624435	B2	20030923		
	WO 2002079778	A2	20021010	WO 2002-US3984	20020207
	WO 2002079778	A3	20030710		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002184941	A1	20021212	US 2002-156165	20020528
	US 6571608	B2	20030603		

AB Various methods are provided for detg. and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least 1 drug. Agents effective to regulate at least 1 of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

IT **28721-07-5**, Oxcarbazepine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vivo delivery methods and compns.)

RN 28721-07-5 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo- (8CI, 9CI) (CA INDEX NAME)



L13 ANSWER 39 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

Citing References

2003:284099 Document No. 138:292806 Galenic form of oral microparticles for slow release. Legrand, Valerie; Castan, Catherine; Meyrueix, Remi; Soula, Gerard (Flamel Technologies, Fr.). Fr. Demande FR 2830447 A1 20030411, 29 pp. (French). CODEN: FRXXBL. APPLICATION: FR 2001-12999 20011009.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2830447	A1	20030411	FR 2001-12999	20011009
	WO 2003030878	A2	20030417	WO 2002-FR3443	20021009
	WO 2003030878	A3	20031204		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AB Slow-release oral microparticles (200 to 600 μm) are disclosed. The release of active principle is based on a double mechanism of release, e.g. "time dependent" and "pH dependent". Slow-release microcapsules contg. metformin hydrochloride with double mechanisms of release are prepd.

IT **298-46-4**, Carbamazepine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(galenic form of oral microparticles for slow release)

RN 298-46-4 CAPLUS

CN 5H-Dibenz[b,f]azepine-5-carboxamide (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



=> **logoff**

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD: